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  HOMEOSTATIC	  SYNAPTIC	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  BY	  AMYLOID	  BETA	  IN	  
CULTURED	  RAT	  HIPPOCAMPAL	  NEURONS	  
	  
JAMES	  GILBERT	  
	  ABSTRACT	  	  	  Accumulation	  of	  amyloid	  beta	  (Aβ)	  in	  the	  brain	  is	  a	  pathological	  hallmark	  of	  Alzheimer’s	  disease	  (AD)	  and	  has	  been	  shown	  to	  lead	  to	  synaptic	  dysfunction	  and	  cognitive	  decline.	  Recent	  studies	  have	  indicated	  synapse	  dysfunction	  as	  an	  early	  pathology	  in	  AD,	  but	  how	  synaptic	  function	  is	  altered	  by	  Aβ	  remains	  unclear.	  We	  hypothesize	  that	  neuronal	  functional	  stability	  may	  be	  altered	  by	  Aβ	  via	  dysregulation	  of	  homeostatic	  synaptic	  plasticity	  (HSP),	  a	  negative-­‐feedback-­‐based	  regulation	  that	  serves	  to	  restrain	  neuronal	  activity	  within	  a	  physiological	  range.	  Here,	  I	  show	  that	  Aβ	  can	  regulate	  HSP	  in	  response	  to	  activity	  deprivation	  with	  an	  over	  scaling	  up	  of	  postsynaptic	  AMPAR	  expression	  and	  excitatory	  synaptic	  currents.	  Aβ	  treatment	  during	  activity	  deprivation	  increases	  the	  surface	  expression	  of	  both	  calcium-­‐permeable	  (Cp),	  GluA2-­‐lacking	  (CpAMPARs)	  and	  regular,	  GluA2-­‐containing	  AMPARs.	  This	  in	  turn	  may	  make	  neurons	  more	  vulnerable	  to	  neuronal	  injury	  after	  a	  toxic	  glutamatergic	  challenge.	  Homeostatic	  synaptic	  scaling	  requires	  the	  PI3K/Akt	  signaling	  pathway	  and	  expression	  of	  CpAMPARs.	  Consistent	  with	  this,	  I	  found	  that	  blockade	  of	  either	  PI3K	  or	  CpAMPARs	  occludes	  over-­‐scaling	  in	  the	  presence	  of	  Aβ,	  suggesting	  that	  the	  enhancement	  of	  HSP	  is	  mediated	  through	  homeostatic	  
	  	   	  	   vii	  
mechanisms.	  Furthermore,	  challenging	  neurons	  with	  glutamate	  after	  Aβ-­‐mediated	  enhancement	  of	  HSP	  shows	  increased	  neuronal	  death.	  These	  findings	  provide	  a	  novel	  mechanism	  by	  which	  Aβ	  alters	  neuronal	  plasticity	  and	  calcium	  homeostasis	  in	  the	  brain,	  suggesting	  that	  the	  HSP	  pathway	  may	  be	  a	  target	  in	  clinical	  treatment	  of	  Alzheimer’s	  disease.	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CHAPTER	  ONE:	  INTRODUCTION	  	  
A.	  Synaptic	  plasticity	  overview	  Neural	  networks	   in	   the	  brain	  are	  dynamic	  systems	  constantly	  undergoing	  changes	  in	   functional	   connectivity	  at	   the	   cellular	  and	   synaptic	   level.	   Individual	  neurons,	   as	  well	  as	  entire	  networks	  of	   cells,	   strengthen	  and	  weaken	  synaptic	  connections	  as	  a	  process	  of	  encoding	  and	  responding	  to	  external	  stimuli.	  This	  fundamental	  property	  of	  neuronal	  plasticity	  is	  the	  basis	  of	  learning	  and	  memory	  and	  can	  also	  be	  involved	  in	   compensatory	   processes	   such	   as	   recovery	   after	   neuronal	   injury.	   Surprisingly,	  with	  constant	  changes	  in	  local	  synaptic	  activity	  occurring	  regularly	  throughout	  the	  brain,	  neurons	  are	  able	  to	  maintain	  physiological	  activity	  levels,	  therefore	  avoiding	  aberrant	  synaptic	  signaling	  or	  injury.	  	  The	   strength	   of	   synaptic	   connections	   can	   either	   be	   enhanced	   by	   long-­‐term	  potentiation	  (LTP),	  or	  decreased	  through	   long-­‐term	  depression	  (LTD),	   in	   the	  well-­‐characterized	  form	  of	  synaptic	  modification	  termed	  Hebbian	  plasticity.	  This	  type	  of	  plasticity	  forms	  the	  basis	  of	  learning	  and	  memory	  and	  one	  could	  imagine	  that	  if	  left	  unconstrained,	   a	   dynamic	   system	   such	   as	   this	   could	   experience	   runaway	  network	  fluctuations	   in	  activity	  that	  push	  the	  system	  to	  saturation	  or	  quiescence.	  However,	  neuronal	   networks	   within	   the	   brain	   are	   constructed	   in	   such	   a	   manner	   that	  alterations	   in	   synaptic	   strength	  are	  balanced	  by	  another	  distinct	   form	  of	  neuronal	  modulation,	   homeostatic	   synaptic	   plasticity	   (HSP).	   These	   two	   forms	   of	   plasticity	  therefore	  co-­‐exist	   to	  adapt	   to	  our	  ever-­‐changing	  sensory	  world,	  while	  maintaining	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the	   balance	   of	   neural	   activity	   within	   a	   physiological	   range	   (Burrone	   et	   al.,	   2002;	  Davis	   and	   Bezprozvanny,	   2001;	   Turrigiano	   et	   al.,	   1998;	   Turrigiano	   and	   Nelson,	  2004).	   Therefore,	   the	   dysregulation	   of	   neuronal	   plasticity	   has	   been	   a	   focus	   of	  investigation	   for	   deficits	   produced	   in	   neurological	   disorders	   such	   as	   ischemia,	  amyotrophic	   lateral	   sclerosis	   (ALS),	   Parkinson’s	   disease,	   Huntington	   disease	   and	  Alzheimer’s	  disease	  (AD).	  	  	  
B.	  AMPARs	  in	  synaptic	  plasticity	  Ionotropic	   glutamatergic	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	   acid	  (AMPA)	   receptors	   (AMPARs)	  mediate	   the	   vast	  majority	   of	   fast	   excitatory	   synaptic	  transmission	   in	   the	   central	   nervous	   system.	   The	   AMPAR	   is	   a	   heterotetramer	  consisting	  of	  different	  compositions	  of	  the	  four	  subunits	  GluA1-­‐4,	  the	  most	  common	  of	  which	  are	  GluA1/GluA2	  and	  GluA2/GluA3	  combinations	  (Borges	  and	  Dingledine,	  1998;	  Dingledine	  et	  al.,	  1999).	  The	  GluA2	  subunit	   is	  unique	  in	  that	   it	  produces	  the	  ion	  channel’s	  selectivity	  against	  the	  permeability	  of	  calcium,	  only	  allowing	  entry	  of	  sodium	   ions	   into	   the	   cell.	   This	   is	   a	   result	   of	   pre-­‐mRNA	   editing	   that	   yields	   a	  replacement	   of	   the	   genomically	   encoded	   glutamine	   for	   arginine	   in	   the	   second	  transmembrane	  domain	  of	   the	  subunit	   (Higuchi	  et	  al.,	  1993;	  Sommer	  et	  al.,	  1991).	  Therefore,	   because	   the	   editing	   site	   is	   located	   in	   the	   channel	   pore,	   the	   positively	  charged	   arginine	   blocks	   calcium	   influx	   (Jonas	   et	   al.,	   1994;	   Swanson	   et	   al.,	   1997;	  Verdoorn	   et	   al.,	   1991).	   Calcium	   permeable	   AMPARs	   (CpAMPARs)	   lack	   a	   GluA2	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subunit,	  and	  although	  these	  special	  receptors	  typically	  have	  much	  lower	  expression	  levels	   in	   the	   brain,	   they’ve	   been	   linked	   to	  major	   processes	   such	   as	   plasticity	   and	  neurotoxicity	  (Jia	  et	  al.,	  2002;	  Kwak	  and	  Weiss,	  2006;	  Man,	  2011;	  Spaethling	  et	  al.,	  2008;	  Zonouzi	  et	  al.,	  2011).	  	   In	   the	  hippocampus	  and	   cerebral	  neocortex,	  GluA1	  and	  GluA2	   subunits	   are	  predominantly	   expressed,	  with	  much	   lower	   levels	   of	   GluA3	   and	   GluA4.	   Therefore	  pyramidal	   neurons,	   which	   comprise	   the	   majority	   of	   the	   neuronal	   populations	   in	  these	   two	  brain	   regions,	  mostly	   express	  AMPARs	   composed	  of	  heterotetramers	  of	  GluA1	   and	   GluA2	   and	   are	   calcium-­‐impermeable.	   Although	   GluA2/3	   has	   been	  hypothesized	   as	   the	   other	   major	   AMPAR	   heteromer	   in	   cortical	   neurons,	   the	  expression	  of	   the	  GluA3	   subunit	   is	   only	   about	  10%	  of	  GluA1	  or	  GluA2,	   suggesting	  that	   GluA2/3	   heteromers	   are	   not	   one	   of	   the	   predominant	   subunit	   combinations	  (Craig	  et	  al.,	  1993;	  Geiger	  et	  al.,	  1995;	  Tsuzuki	  et	  al.,	  2001).	  Additionally,	  the	  subunit	  composition	  of	  AMPARs	  varies	  across	  neuronal	  populations,	  for	  example	  GABAergic	  interneurons,	  which	   represent	   about	   10%	   of	   the	   total	   neuronal	   population	   in	   the	  brain,	   have	   very	   low	   GluA2	   subunit	   expression	   with	   subsequently	   low	   levels	   of	  CpAMPARs	   (Geiger	   et	   al.,	   1995;	   Koh	   et	   al.,	   1995;	   McBain	   and	   Dingledine,	   1993).	  Cerebellar	   purkinje	   cells	   on	   the	   other	   hand,	   have	   an	  unusually	   high	   expression	   of	  CpAMPARs	  and	  have	  been	  linked	  with	  neurotoxcity	  in	  this	  region	  in	  ALS	  (Bliss	  et	  al.,	  2011;	  Kwak	  and	  Weiss,	  2006).	  The	  majority	  of	  AMPARs	  in	  the	  mature	  brain	  contain	  the	  edited	  GluA2	  subunit,	  and	  are	  therefore	  calcium-­‐impermeable	  (Hollmann	  et	  al.,	  1991),	   	   and	  under	  basal	   conditions	  only	  8%	  of	  AMPARs	   in	  CA1/CA2	  hippocampal	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neurons	   are	  GluR1	  homomers,	   and	   therefore	   calcium-­‐permeable	   (Wenthold	   et	   al.,	  1996).	  AMPARs	  are	   localized	  and	  highly	  enriched	  at	   the	  postsynaptic	  domain,	   and	  accumulation	   is	   stabilized	   and	   regulated	  by	   interactions	  with	   cytosolic	   scaffolding	  proteins	  such	  as	  GRIP,	  GRASP,	  SAP97,	  PICK1,	  Stargazin	  and	  PSD-­‐95.	  These	  AMPAR-­‐associated	  proteins	  usually	  contain	  one	  or	  more	  PDZ	  domains	  that	  interact	  with	  the	  intracellular	   C-­‐terminus	   of	   GluA	   subunits	   to	   regulate	   AMPAR	   synaptic	   targeting,	  intracellular	  trafficking,	  as	  well	  as	  channel	  function	  (Kim	  and	  Sheng,	  2004;	  Song	  and	  Huganir,	  2002;	  Tomita	  et	  al.,	  2001).	  	  A	   large	  number	  of	   studies	  have	   established	   that	  AMPARs	   are	  not	   passively	  localized	   at	   the	   postsynaptic	   domain.	   Instead	   they	   are	   very	   dynamic,	   trafficking	  constantly	   between	   the	   plasma	  membrane	   and	   intracellular	   compartments	   (Bredt	  and	  Nicoll,	  2003;	  Malenka,	  2003;	  Malinow	  and	  Malenka,	  2002;	  Schwarz	  et	  al.,	  2010).	  AMPARs,	   like	   other	   membrane	   proteins,	   are	   synthesized	   in	   the	   endoplasmic	  reticulum	   and	   following	   further	  modification	   in	   the	  Golgi,	   are	   transported	   to,	   and	  inserted	  into	  the	  plasma	  membrane.	  Pre-­‐existing	  surface	  AMPARs	  are	  endocytosed	  through	  the	  clathrin-­‐coated	  pit	  pathway,	  where	  they	  can	  either	  be	  degraded	  through	  the	  ubiquitin	  proteasomal	  system,	  or	  trafficked	  for	  re-­‐insertion	  into	  the	  membrane.	  During	   basal	   conditions,	   a	   balance	   between	   the	   opposing	   processes	   of	   receptor	  insertion	  and	  internalization	  maintains	  a	  stable	  surface	  expression	  level	  of	  AMPARs.	  Therefore,	   with	   the	   induction	   of	   synaptic	   plasticity,	   the	   rates	   of	   internalization	  
	  	   	  
5	  
and/or	  insertion	  of	  AMPARs	  can	  be	  up-­‐	  or	  down-­‐regulated	  to	  increase	  or	  decrease	  surface	  AMPAR	  expression.	  	  
C.	   HSP	   is	   expressed	   via	   the	   scaling	   up	   of	   surface	   postsynaptic	   AMPAR	  
abundance	  	  Homeostatic	   synaptic	   plasticity	   aims	   to	   maintain	   activity	   within	   a	   physiological	  range	  at	  the	  individual	  neuronal	  level	  in	  response	  to	  global	  changes	  in	  the	  network.	  This	   can	   be	   achieved	   through	   adjustments	   in	   the	   strength	   of	   synaptic	   inputs,	  neuronal	   excitability,	   neuronal	   connectivity,	   or	   in	   the	   balance	   between	   excitation	  and	  inhibition.	  Among	  these	  variables,	  the	  regulation	  of	  synaptic	  strength	  has	  been	  the	   most	   extensively	   investigated	   and	   believed	   to	   be	   the	   crucial	   measure	   in	  homeostatic	  regulation.	  This	  is	  known	  as	  homeostatic	  synaptic	  plasticity	  (HSP)	  and	  is	   expressed	   mainly	   through	   the	   alteration	   in	   postsynaptic	   AMPAR	   accumulation	  (Burrone	   et	   al.,	   2002;	   Davis	   and	   Bezprozvanny,	   2001;	   Turrigiano	   et	   al.,	   1998).	  During	  HSP,	  surface	  AMPAR	  accumulation	  at	  the	  postsynaptic	  membrane	  are	  scaled	  up-­‐	  or	  down	   in	   response	   to	  hypo-­‐	  or	  hyperactivity	   levels,	   respectively.	  Changes	   in	  synaptic	  surface	  levels	  of	  AMPARs	  are	  thought	  to	  be	  regulated	  via	  modulation	  of	  the	  rates	  of	  insertion	  of	  new,	  or	  endocytosis	  of	  existing,	  receptors	  (Figure	  1).	  
	   The	  most	  commonly	  studied	  model	  of	  HSP	  is	  during	  activity	  deprivation	  with	  the	   application	   of	   the	   voltage-­‐gated	   sodium	   channel	   blocker	   tetrodotoxin	   (TTX).	  When	   neurons	   are	   chronically	   incubated	  with	   TTX	   to	   abolish	   action	   potentials	   in	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vitro,	   thus	   silencing	   network	   activity,	   the	   synapse	   responds	   in	   a	   compensatory	  manner	   resulting	   in	   an	   increase	   in	   the	   strength	   of	   AMPAR-­‐mediated	   synaptic	  transmission	  (Rabinowitch	  and	  Segev,	  2008;	  Turrigiano	  et	  al.,	  1998;	  Wierenga	  et	  al.,	  2005).	   With	   the	   measurement	   of	   miniature	   excitatory	   postsynaptic	   currents	  (mEPSCs)	   of	   AMPARs,	   it	   has	   been	   shown	   that	   chronic	   suppression	   of	   network	  activity	   results	   in	   a	   scaling	   up	   of	   the	   post-­‐synaptic	   response,	   indicated	   by	   an	  increase	   in	   average	   mEPSC	   amplitude	   (Desai	   et	   al.,	   2002;	   Gainey	   et	   al.,	   2009;	  Turrigiano	   et	   al.,	   1998).	   Conversely,	   chronic	   network	   hyperactivation,	   commonly	  induced	  by	  bath	  application	  of	  bicuculline,	  an	  antagonist	  of	  the	  inhibitory	  ionotropic	  gamma	   amino	   butyric	   acid	   A	   (GABAA)	   receptors,	   results	   in	   a	   homeostatic	  downscaling	  in	  AMPAR	  mediated	  mEPSC	  amplitude	  (Turrigiano	  et	  al.,	  1998).	  	  	  
D.	  Implications	  of	  Aβ	  in	  disrupted	  synaptic	  plasticity	  and	  calcium	  signaling	  AD	   is	   characterized	   by	   early	   deficits	   in	   learning	   and	   memory	   with	   an	  eventual	  loss	  of	  higher	  cognitive	  functions.	  A	  predominant	  pathological	  hallmark	  in	  AD	  brains	  is	  an	  increased	  presence	  of	  amyloid	  beta	  (Aβ),	  a	  peptide	  generated	  from	  the	   amyloid	  precursor	  protein	   (APP).	  Emerging	   evidence	   suggests	   that	   soluble	  Aβ	  oligomers	  adversely	  affect	  synaptic	  function,	  which	  eventually	  leads	  to	  the	  cognitive	  failure	  associated	  with	  AD.	  One	  of	   the	  hallmark	  characteristics	  of	  Aβ	   toxicity	   is	  an	  observed	  decrease	   in	  neuronal	   excitability.	  Recent	   studies	  have	   suggested	   that	  Aβ	  induces	   the	   loss	   of	   AMPARs	   at	   the	   synaptic	   surface,	   and	   this	   decrease	   underlies	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synaptic	   depression	   and	  dendritic	   spine	   loss	   (Hsieh	   et	   al.,	   2006a).	   In	  vitro	   studies	  performed	  in	  hippocampal	  neurons	  have	  reported	  that	  application	  of	  Aβ	  peptides,	  at	  concentrations	  below	  neurotoxic	  levels,	  can	  inhibit	  LTP	  induction	  without	  affecting	  basal	  synaptic	  transmission	  (Chen	  et	  al.,	  2000;	  Chen	  et	  al.,	  2002;	  Zhao	  et	  al.,	  2004).	  A	  similar	  result	  was	  shown	   in	  vivo,	  where	  cerebral	   injection	  of	  naturally	  secreted	  Aβ	  collected	  from	  cells	  expressing	  mutated	  APP	  (containing	  the	  V717F	  mutation	  in	  APP	  resulting	  in	  the	  production	  of	  longer	  Aβ	  peptides)	  prevented	  the	  stable	  maintenance	  of	   LTP	   in	   the	   hippocampal	   CA1	   region	   (Walsh	   et	   al.,	   2002).	   Soluble	   Aβ	   oligomers	  were	  also	  shown	  to	  be	  responsible	  for	  blocking	  LTP	  induction	  (Walsh	  et	  al.,	  2002),	  and	   in	   vivo	   injection	   of	   Aβ	   is	   reported	   to	   facilitate	   LTD	   and	   LTP	   reversal	  (depotentiation)	   in	   the	   CA1	   region	   of	   the	   hippocampus	   (Kim	   et	   al.,	   2001).	   The	  majority	   of	   studies	   suggest	   that	  while	   fibrillar	   Aβ	   accumulation	   is	   found	   in	   senile	  plaques	  in	  AD,	  it	  is	  the	  soluble	  Aβ	  oligomers	  that	  disturb	  synaptic	  function	  and	  may	  lead	   to	   the	   later	  onset	  neurodegeneration	  (Tanzi,	  2005;	  Walsh	  et	  al.,	  2002).	  These	  findings	   suggest	   that	   an	   excess	   presence	   of	   the	   soluble	   small	   species’	   of	   Aβ	   can	  impair	   synaptic	   function	   as	  well	   as	   the	  mechanisms	   that	   regulate	   synaptic	   scaling	  and	  regulation	  (Chapman	  et	  al.,	  1999;	  Hsia	  et	  al.,	  1999;	  Larson	  et	  al.,	  1999;	  Li	  et	  al.,	  2009;	   Li	   et	   al.,	   2011;	   Tanzi	   and	   Bertram,	   2005;	   Walsh	   and	   Selkoe,	   2004a;	  Westerman	  et	  al.,	  2002).	  These	  studies	  have	  provided	  great	  insight	  into	  the	  disease	  pathology	   of	   AD,	   however,	   it	   has	   become	   increasingly	   clear	   that	   cognitive	   decline	  should	   be	   examined	   from	   a	   much	   broader	   perspective.	   HSP	   is	   a	   mechanism	  employed	   to	   maintain	   neuronal	   stability	   and	   function	   in	   response	   to	   dynamic	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changes	   within	   a	   system	   over	   extended	   periods	   of	   time.	   In	   contrast,	   Hebbian	  plasticity	   mechanisms	   work	   in	   a	   synaptic	   input	   specific	   manner	   over	   relatively	  shorter	   periods	   of	   time.	   Neurons	   do	   not	   function	   in	   isolation,	   therefore	   a	   better	  assessment	  of	  Aβ’s	  effects	  on	  synaptic	  plasticity	  should	  involve	  the	  investigation	  of	  global	   changes	   in	   synaptic	   connectivity.	   Aberrations	   in	   HSP	   could	   have	   profound	  effects	  on	  neuronal	  health	  and	  network	  integrity,	  possibly	  resulting	  in	  the	  synaptic	  deficits	  and	  neurodegeneration	  in	  diseases	  such	  as	  AD.	  Aβ	   is	   also	   known	   to	   interact	   with	   NMDARs,	   subsequently	   elevating	  intracellular	  Ca2+	   levels,	   thus	  producing	  excitotoxicity	   (De	  Felice	  et	  al.,	  2007;	  Kelly	  and	  Ferreira,	  2006;	  Pellistri	  et	  al.,	  2008).	  Activation	  of	  NMDARs	  is	  hypothesized	  to	  occur	   during	   late-­‐stage	   AD,	  when	  Aβ	   plaque	   formation	   is	  most	   evident.	   However,	  there	  is	  strong	  evidence	  in	  recent	  findings	  that	  AMPAR	  trafficking	  is	  dysregulated	  by	  the	   presence	   of	   Aβ	   in	   the	   initial	   stages	   of	   AD.	   The	   change	   in	   AMPAR	   surface	  expression	   results	   in	   a	   disruption	   of	   glutamatergic	   synaptic	   transmission	   which	  correlates	  with	   the	  observed	   early	  deficits	   in	   cognitive	   ability	   (Parameshwaran	   et	  al.,	  2008).	  	  Calcium-­‐mediated	   signal	   transduction	   connects	   membrane	   excitability	   and	  neuronal	  functions	  ranging	  from	  proliferation,	  cell	  death,	  secretory	  pathways,	  gene	  expression,	   and	   memory	   formation.	   Neuronal	   Ca2+	   influx	   can	   be	   maintained	   by	  different	   Ca2+-­‐permeable	   channels,	   such	   as	   voltage-­‐gated	   Ca2+	   channels	   of	   the	  plasma	  membrane,	  NMDARs,	   CpAMPARs,	   nicotinic	   receptors,	   store-­‐operated	   	   Ca2+	  channels,	  or	  from	  intracellular	  stores	  in	  the	  endoplasmic	  reticulum	  (ER)	  via	  inositol-­‐
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1,4,5-­‐trisphosphate	   receptors	   (InsP3R)	   and	   ryanodine	   receptors	   (RyRs).	   Ca2+-­‐permeable	  ion	  channels	  play	  a	  prominent	  role	  in	  many	  integral	  aspects	  of	  neuronal	  function,	   as	   they	   are	   a	   link	   between	   synaptic	   transmission	   and	   cellular	   signaling	  pathways.	   Due	   to	   calcium’s	   importance	   as	   a	   second	   messenger,	   neurons	   tightly	  regulate	   intracellular	   Ca2+	   levels,	   mainly	   via	   local	   signal	   transduction	   pathways.	  Decreases	   in	   Ca2+	   levels	   can	   lead	   to	   abnormal	   functioning	   of	   neurons,	   whereas	  excessive	  Ca2+	  levels	  cause	  cell	  death	  (Berridge	  et	  al.,	  1998).	  Therefore,	  even	  small	  fluctuations	   in	   Ca2+	   content	   can	   be	   highly	   damaging	   over	   the	   long	   lifetime	   of	   a	  neuron	  (Khachaturian,	  1989).	  	  Although	   the	  exact	  mechanism	  of	  how	  Aβ	  mediates	  AD	  pathogenesis	   is	  not	  fully	   understood,	   there	   are	   observations	   that	   link	   Aβ	   accumulation	  with	   elevated	  intracellular	   Ca2+	   levels	   in	   vivo	   (Kuchibhotla	   et	   al.,	   2008).	   It’s	   been	   shown	   that	  soluble	   oligomeric	   forms	   of	   Aβ	   increase	   Ca2+	   release	   from	   the	   ER	   with	   the	  stimulated	  production	  of	  inositol	  trisphosphate	  (Demuro	  and	  Parker,	  2013).	  Aβ	  has	  also	  been	  shown	  to	  activate	  synaptic	  mGluR5	  receptors	  (Renner	  et	  al.,	  2010;	  Um	  et	  al.,	  2013)	  and	  NMDARs	  (De	  Felice	  et	  al.,	  2007;	  Kelly	  and	  Ferreira,	  2006;	  Pellistri	  et	  al.,	   2008)	   leading	   to	   increased	   calcium	   signaling	   and	   the	   disruption	   of	   neuronal	  function.	  With	  calcium’s	   important	  role	   in	   the	  regulation	  and	   initiation	  of	  synaptic	  plasticity,	   and	  Aβ’s	   link	   to	  aberrant	   calcium	  signaling,	  we	  postulated	   that	  elevated	  levels	  of	  the	  pathogenic	  Aβ	  peptide	  could	  disrupt	  the	  regulation	  of	  HSP.	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E.	  Important	  signaling	  pathways	  in	  HSP	  are	  implicated	  in	  AD	  pathogenesis	  	  	  The	   regulation	   of	   stable	   neuronal	   activity	   levels	   is	   integral	   in	  maintaining	   proper	  brain	  function.	  Therefore,	  dysregulation	  of	  HSP	  may	  be	  involved	  in	  cognitive	  decline	  in	   neurological	   disorders	   such	   as	   AD.	   Long-­‐lasting	   changes	   in	   neuronal	   activity,	  including	   a	  misbalance	   of	   excitation	   and	   inhibition,	   and	   calcium	  homeostasis,	  will	  compromise	   network	   integrity	   and	   neuronal	   conditions.	   Furthermore,	   since	  glutamate	  receptors	  play	  a	  key	  role	  in	  excitotoxicity,	  dysregulated	  HSP	  may	  lead	  to	  calcium	   overload	   and	   neuronal	   death	   via	   alterations	   in	   glutamate	   receptor	  accumulation	   at	   synapses.	   The	   involvement	   of	   the	   homeostatic	   response	   in	   the	  pathogenesis	  of	  neurological	  disorders	  has	  only	  recently	  been	  examined,	  but	  its	  role	  in	  AD	  remains	  less	  clear.	  	  Most	   AMPARs	   contain	   at	   least	   one	   GluA2	   subunit	   under	   physiological	  conditions	  and	  allow	  only	  sodium	  influx	  during	  synaptic	  activation.	  When	  AMPARs	  are	  composed	  without	  GluA2	  subunits,	  the	  receptor	  channel	  will	  permeate	  calcium	  in	   addition	   to	   sodium.	   Due	   to	   a	   channel	   blockade	   by	   intracellular	   polyamines	   at	  positive	   membrane	   potentials,	   calcium-­‐permeable	   AMPARs	   (CpAMPARs)	   show	   a	  signature	   feature	   of	   attenuated	   currents	   at	   depolarized	   membrane	   potentials,	  producing	  an	  inward	  rectification	  in	  the	  current-­‐voltage	  relationship	  (Hollmann	  and	  Heinemann,	  1994;	  Sprengel	  and	  Seeburg,	  1993).	   Studies	  have	  also	   shown	   that	   the	  expression	   of	   CpAMPARs	   is	   regulated	   during	   development,	   changes	   in	   synaptic	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activity,	  or	  pathological	  challenges	  such	  as	  ischemia	  and	  ALS.	  (Hou	  et	  al.,	  2008;	  Ju	  et	  al.,	  2004;	  Peng	  et	  al.,	  2006;	  Sutton	  et	  al.,	  2006;	  Thiagarajan	  et	  al.,	  2005).	  At	   early	   postnatal	   time	   points,	   recordings	   from	   cortical	   pyramidal	   neurons	  show	   higher	   inward	   rectification	   in	   AMPAR-­‐mediated	   synaptic	   currents,	   which	  diminish	  with	   age,	   indicating	   a	   developmental	   switch	   in	   AMPAR	   composition	   and	  calcium	  permeability	  (Kumar	  et	  al.,	  2002).	  By	  providing	  an	  unconventional	  source	  of	  calcium	  other	  than	  NMDAR	  or	  calcium	  channels,	  GluA2-­‐lacking	  AMPARs	  may	  play	  an	  important	   role	   in	   synaptic	   plasticity.	   Importantly,	   with	   the	   expression	   of	  hippocampal	   LTP,	   GluA2-­‐lacking	   AMPARs	   are	   first	   incorporated	   into	   the	   synapse,	  and	  are	  subsequently	  replaced	  with	  GluA2-­‐containing	  AMPARs	  (Plant	  et	  al.,	  2006).	  In	   cerebellar	   stellate	   cells,	   which	   normally	   contain	   GluA2-­‐lacking	   AMPARs,	   high-­‐frequency	   presynaptic	   activity	   induces	   a	   calcium-­‐dependent	   increase	   in	   synaptic	  insertion	  of	  GluA2-­‐containing	  AMPARs	   (Liu	   and	  Cull-­‐Candy,	   2000).	  These	   findings	  strongly	   indicate	   the	  presence	  of	  a	  self-­‐regulating	  mechanism	  in	  which	  CpAMPAR-­‐mediated	   calcium	   influx	   triggers	   the	   recruitment	   of	   normal	   GluA2-­‐containing	  AMPARs	   to	   synapses,	   with	   the	   possibility	   that	   disruptions	   in	   the	   temporal	  expression	  of	  CpAMPARs	  may	  lead	  to	  dysregulated	  HSP	  and/or	  cytotoxicity.	  Activity	   deprivation	   has	   been	   shown	   to	   induce	   inward	   rectification	   in	   the	  current-­‐voltage	  relationship	  of	  AMPAR	  mediated	  current,	  suggesting	  an	  increase	  in	  the	  expression	  of	  GluA2-­‐lacking,	  CpAMPARs	  (Aoto	  et	  al.,	  2008;	  Ju	  et	  al.,	  2004;	  Sutton	  et	   al.,	   2006;	   Thiagarajan	   et	   al.,	   2005).	   Consistent	   with	   this,	   following	   treatment	  paradigms	   for	   homeostatic	   plasticity,	   AMPAR-­‐mediated	   currents	   become	   sensitive	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to	  CpAMPAR-­‐selective	  antagonists	  philanthotoxin-­‐433	  (PhTx)	  or	  1-­‐naphthyl	  acetyl	  spermine	  (Naspm)	  (Aoto	  et	  al.,	  2008;	  Hou	  et	  al.,	  2008;	  Ju	  et	  al.,	  2004;	  Sutton	  et	  al.,	  2006;	  Thiagarajan	  et	  al.,	  2005).	  Interestingly,	  the	  blockade	  of	  homeostatic	  plasticity	  is	  observed	  only	  when	  a	  CpAMPAR	  antagonist	   is	  applied	  during	   the	  early	   stage	  of	  activity	  deprivation	  (Hou	  et	  al.,	  2008),	  indicating	  that	  CpAMPARs	  are	  needed	  for	  the	  initiation,	  but	  not	  maintenance,	  of	  homeostatic	  synaptic	  regulation.	  Neuronal	   treatment	   with	   exogenous	   Aβ	   in	   vitro	   is	   known	   to	   increase	  inflammatory	  cytokine	  production,	   including	   tumor	  necrosis	   factor-­‐α	   (TNF-­‐α)	   (Lin	  et	  al.,	  2013).	  Dysregulation	  of	  TNF-­‐α	  production	  has	  been	  implicated	  in	  a	  variety	  of	  human	   diseases	   including	   AD	   (Swardfager	   et	   al.,	   2010),	   cancer	   (Locksley	   et	   al.,	  2001),	   and	  major	   depression	   (Dowlati	   et	   al.,	   2010).	   TNF-­‐α	   can	   be	   expressed	   as	   a	  transmembrane	  protein,	  or	  released	  via	  proteolytic	  cleavage	  by	  the	  TNF-­‐α	  cleavage	  enzyme	  (TACE)	  as	  soluble	  cytokine	  that	  can	  activate	  the	  phosphoinositide	  3-­‐kinase	  (PI3K)-­‐Akt	  pathway	  (Black	  et	  al.,	  1997).	   Interestingly,	  an	  enhanced	  delivery	  of	   the	  GluA1	   subunit	   over	   GluA2	   occurs	   after	   TNF-­‐α	   treatment	   in	   vitro	   (Stellwagen	   and	  Malenka,	   2006),	   leading	   to	   the	   generation	   of	   GluA2-­‐lacking	   AMPARs,	   which	   may	  play	   an	   important	   role	   in	   the	   initiation	   of	   the	   homeostatic	   response	   as	   discussed	  previously	  (Man,	  2011).	  Importantly,	  it	  has	  been	  shown	  that	  glial	  produced	  TNFα	  is	  necessary	   for	   the	   synaptic	   scaling	   up	   of	   AMPARs	   after	   activity	   deprivation	   with	  prolonged	  exposure	   to	  TTX	  (Stellwagen	  and	  Malenka,	  2006).	  After	   treatment	  with	  the	  cytokine,	  cultured	  neurons	  show	  a	  rapid	  recruitment	  of	  AMPARs	  to	  the	  surface,	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which	  can	  be	  significantly	  enhanced	  with	  the	  activation	  of	  downstream	  PI3K	  (Figure	  1)	  (Beattie	  et	  al.,	  2002;	  Leonoudakis	  et	  al.,	  2008;	  Stellwagen	  et	  al.,	  2005).	  AMPAR	  trafficking,	  synaptic	  plasticity	  and	  memory	  consolidation	  have	  been	  linked	  to	  activation	  of	  the	  PI3K–Akt	  pathway	  (Gobert	  et	  al.,	  2008;	  Lin	  et	  al.,	  2001).	  In	  LTP	   paradigms,	   AMPAR	   insertion	   is	   dependent	   upon	   PI3K	   activation	   in	   cultured	  neurons	   (Man	  et	  al.,	  2003;	  Schratt	  et	  al.,	  2004),	  and	  PI3K	  activation	   is	   required	   for	  LTP	  maintenance	  in	  CA1	  hippocampal	  neurons	  in	  vivo	  (Gobert	  et	  al.,	  2008).	  The	  role	  this	  pathway	  plays	  in	  HSP	  has	  yet	  to	  be	  fully	  elucidated,	  however,	  TNFα	  is	  known	  to	  activate	  PI3K	  and	  increase	  surface	  expression	  of	  AMPARs	  during	  activity	  deprivation	  (He	   et	   al.,	   2012).	   Silencing	   pre-­‐synaptic	   activity	   via	   overexpression	   of	   Kir2.1,	   an	  inwardly	   rectifying	   potassium	   channel,	   first	   linked	   the	   PI3K/Akt	   pathway	   to	   HSP	  showing	   that	   postsynaptic	   increases	   in	   AMPAR	   surface	   expression	  were	   abolished	  with	  the	  application	  of	  the	  PI3K	  inhibitor	  Wortmannin	  (Hou	  et	  al.,	  2008).	  Presenilin	   1	   (PS1)	   is	   an	   integral	   component	   of	   γ-­‐secretase,	   an	   enzyme	  involved	   in	   the	   proteolytic	   cleavage	   of	   APP	   and	   generation	   of	   the	   pathogenic	   Aβ	  species	   (De	   Strooper,	   2003;	   Tanzi	   and	   Bertram,	   2001).	   PS1	   also	   activates	   the	  PI3K/Akt	  pathway	  via	  promotion	  of	  N-­‐cadherin/PI3K	  complex	  formation,	  activating	  Akt	  downstream	  (Baki	  et	  al.,	  2004).	  Studies	  have	  shown	  that	  the	  global	  homeostatic	  scaling	  up	  of	  mEPSCs	   induced	  by	  prolonged	  TTX	   treatment	   is	   impaired	   in	   cultured	  hippocampal	   neurons	   derived	   from	   PS1	   knockout	   mice,	   suggesting	   a	   possible	  involvement	  of	   the	  PI3K	   cascade	   (Pratt	   et	   al.,	   2011).	   In	   support	   of	   this	   hypothesis,	  overexpression	  of	  constitutively	  active	  Akt	  rescues	  impaired	  global	  synaptic	  scaling	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Figure	  1.	  Expression	  of	  AMPAR-­‐mediated	  HSP.	  A.	  Increased	  internalization	  of	  AMPARs	  during	  periods	  of	  hyperactivity	  results	  in	  receptor	  degradation	  and/or	  recycling.	   B.	   During	   basal	   conditions,	   there	   is	   a	   balance	   between	   AMPAR	  insertion	   and	   internalization	   resulting	   in	   a	   stable	   level	   of	   surface	   receptor	  expression.	  C.	  During	  prolonged	  periods	  of	   activity	  deprivation,	  CpAMPARs	  are	  first	   inserted	   into	   the	   membrane	   followed	   by	   the	   insertion	   of	   normal,	   GluA2-­‐containing	   AMPARs.	   One	   pathway,	   TNF-­‐α-­‐mediated	   activation	   of	   PI3K,	   is	  implicated	  in	  Alzheimer’s	  disease.	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F.	  Research	  aims	  This	  research	  aims	   to	  study	   the	  regulation	  of	  HSP	  by	  Aβ	  and	   the	   implications	   that	  arise	   from	   dysregulated	   homeostatic	   responses.	   Synaptic	   depression	   and	  aberrations	   in	   synaptic	  plasticity	  due	   to	   excessive	   levels	   of	  Aβ	  have	  been	   causally	  implicated	  in	  the	  cognitive	  deficits	  and	  neurodegeneration	  in	  AD	  patients	  (Chapman	  et	  al.,	  1999;	  Fitzjohn	  et	  al.,	  2001;	  Hsia	  et	  al.,	  1999;	  Larson	  et	  al.,	  1999;	  Li	  et	  al.,	  2009;	  Li	   et	   al.,	   2011;	  Westerman	   et	   al.,	   2002).	   One	   common	   element	   in	   AD	   is	   disrupted	  neuronal	   calcium	   signaling.	   Increased	   intracellular	   calcium	   levels	   are	   functionally	  linked	   to	   the	   pathological	   phenotypes	   seen	   in	   AD	   such	   as	   amyloid	   plaques	   and	  synaptic	   dysfunction	   (Chakroborty	   and	   Stutzmann,	   2011).	   It	   is	   possible	   that	   Aβ	  shifts	  the	  threshold	  of	  homeostatic	  regulation,	  possibly	  through	  upstream	  signaling	  pathways	   such	   as	   PI3K/Akt	   and/or	   CpAMPARs.	   Therefore,	   a	   normal	   downturn	   in	  neuronal	   activity	   may	   trigger	   a	   homeostatic	   over-­‐response	   leading	   to	   synaptic	  hyperactivation	   and	   elevated	   calcium	   influx,	   leading	   to	   cell	   death.	   A	   better	  understanding	  of	  the	  regulation	  of	  these	  processes	  and	  their	  link	  to	  Aβ	  and	  AD,	  will	  be	   instrumental	   in	   elucidating	   the	   underlying	   molecular	   mechanisms	   of	   this	  debilitating	  neurological	  disease.	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CHAPTER	  TWO:	  MATERIALS	  AND	  METHODS	  
Materials	  
Drugs	  and	  reagents.	  TTX,	  APV	  and	  PhTx	  were	  purchased	  from	  Sigma	  Aldrich	  and	  prepared	  in	  water.	  Bicuculline	  was	  purchased	  from	  Tocris	  Biocience	  and	  prepared	  in	  DMSO.	  All	  drugs	  were	  prepared	  at	  1000X	  stock	  solution,	  stored	  in	  aliquots	  at	  −20°C	  and	  thawed	  only	  once	  prior	  to	  use	  to	  preserve	  their	  potency.	  A	  mouse	  monoclonal	  GluA1	  N-­‐terminal	  antibody	  was	  purchased	  from	  Millipore	  and	  stored	  at	  −20°C	  until	  use	  for	  surface	  GluA1	  immunocytochemistry.	  Alexa-­‐Fluor	  conjugated	  secondary	  antibodies	  were	  purchased	  from	  Invitrogen,	  and	  Hoescht	  stain	  and	  propidium	  iodide	  were	  purchased	  from	  Sigma	  Aldrich	  and	  stored	  at	  −20°C	  until	  use.	  	  
Amyloid	  beta.	  Synthetic	  Aβ	  [1-­‐42]	  was	  purchased	  from	  Invitrogen	  and	  prepared	  according	  to	  the	  manufacturer’s	  instructions.	  Briefly,	  the	  peptide	  was	  dissolved	  in	  HPLC	  grade	  water	  at	  1mM	  then	  diluted	  to	  200μM	  and	  incubated	  at	  37°C	  for	  36	  hours.	  Samples	  were	  aliquoted,	  stored	  at	  −20°C,	  and	  thawed	  once	  directly	  prior	  to	  use.	  	  
Methods	  
Neuronal	   cultures.	   Primary	   hippocampal	   cultures	   were	   prepared	   from	   embryonic	  day	  18	  rat	  embryos	  as	  previously	  described	  (Man	  et	  al.,	  2007).	  Cells	  (0.4–0.6	  ×	  106)	  were	  plated	  into	  a	  60-­‐mm	  dish	  with	  polylysine-­‐precoated	  coverslips	  and	  maintained	  in	   neurobasal	   medium	   that	   was	   replenished	   twice	   a	   week.	   Because	   typical	   HSP	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mainly	   occurs	   in	   younger	   neurons	   in	   vitro,	   cultures	   were	   treated	   and	   recorded	  between	  14-­‐16	  days	  in	  vitro.	  	  	  
Drug	  and	  Aβ	  treatment.	  Drugs	  were	  added	  directly	  to	  the	  culture	  medium	  at	  DIV	  14-­‐16	  (1μM	  TTX,	  20μM	  Bicuculline,	  50μM	  APV,	  5μM	  PhTx)	  and	  allowed	  to	  incubate	  for	  24	   hours	   in	   the	   HSP	   paradigm	   described	   previously	   (Turrigiano	   et	   al.,	   1998).	   Aβ	  (0.5μM)	   was	   added	   directly	   to	   the	   culture	   medium	   at	   the	   same	   time	   as	   drug	  application	   from	   a	   freshly	   thawed	   aliquot	   of	   200μM	   stock.	   Aβ	   aliquots	   were	   not	  repeatedly	  freeze-­‐thawed	  to	  maintain	  their	  stability.	  	  
Immunocytochemistry.	   Neurons	   were	   washed	   with	   artificial	   cerebrospinal	   fluid	  (ACSF)	   and	   fixed	   with	   4%	   paraformaldehyde/	   4%	   sucrose	   for	   10	   minutes,	   and	  stained	  without	  permeabilization	  for	  surface	  labeling.	  Coverslips	  with	  neurons	  were	  blocked	  with	  10%	  normal	  goat	  serum	  (NGS)	  in	  ACSF	  for	  1	  hour	  and	  then	  incubated	  with	   primary	   antibodies	   dissolved	   in	   5%	   NGS	   in	   ACSF	   for	   2	   hours	   at	   room	  temperature.	   Cells	   were	   then	   washed	   three	   times	   with	   ACSF	   and	   incubated	   with	  fluorescent	  Alexa	  Fluor-­‐conjugated	  secondary	  antibodies	  (1:700)	  for	  1	  hour	  prior	  to	  visualization.	   Coverslips	   were	   mounted	   onto	   slides	   with	   Prolong	   Gold	   Anti-­‐fade	  Reagent	  for	  viewing	  on	  the	  microscope.	  	  
Cell	  death	  assay.	  30μM	  glutamate	  or	  vehicle	  alone,	  was	  added	  directly	  to	  the	  culture	  medium	  for	  1	  hour	  at	  37°C.	  Cultures	  were	  then	  washed	  three	  times	  with	  ACSF	  and	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fresh	   neurobasal	  medium	  was	   replaced	   to	   allow	   the	   cells	   to	   recover	   for	   2	   hours.	  Cultures	   were	   incubated	   with	   Hoescht	   stain	   (1:1000)	   and	   propidium	   iodide	  (1μg/ml)	  added	  directly	  to	  the	  media	  at	  37°C	  for	  the	  final	  20	  minutes	  of	  recovery.	  Coverslips	  were	  washed	  three	  times	  with	  ACSF,	  fixed	  in	  4%	  paraformaldehyde/4%	  sucrose	   for	   10	  minutes,	   washed	   three	   times	   again	   and	  mounted	   onto	   slides	  with	  Prolong	   Gold	   Anti-­‐Fade	   Reagent	   (Inivitrogen).	   On	   the	   microscope,	   cells	   were	  visualized	  at	  460nm	  (Hoescht)	  and	  615nm	  (propidium	  iodide),	  and	  the	  percentage	  of	  nuclei	  positive	  for	  propidium	  iodide	  was	  calculated.	  	  
Image	   collection.	   Immunostained	   coverslips	   were	   mounted	   onto	   slides	   using	  Prolong	  Gold	  Anti-­‐Fade	  Reagent	  and	  kept	   in	   the	  dark	   for	  >4	  hours	  before	   imaging	  with	   a	   63X	   oil-­‐immersion	   objective,	   a	   DIC	   picture	   was	   taken	   for	   morphology	  purposes.	  Images	  were	  collected	  with	  Axiovision	  4.8	  software	  and	  exposure	  time	  for	  the	   fluorescence	   signal	   was	   adjusted	   manually	   so	   the	   signals	   were	   within	   a	   full	  dynamic	  range.	  Once	  the	  parameters	  were	  set,	  they	  were	  fixed	  and	  used	  throughout	  the	  experiment.	  For	  accurate	  quantification,	  all	  images	  were	  collected	  in	  12-­‐bit	  gray	  scale	  and	  saved	  as	  raw	  data	  analysis	  with	  Image	  J	  software.	  	  	  
Electrophysiology.	  For	  mEPSC	  recordings,	  DIV14-­‐16	  cultured	  hippocampal	  neurons	  were	   treated	  with	  TTX	  (1μM)	   for	  24	  hours	   to	   induce	  HSP.	  The	  coverslip	  was	   then	  transferred	   to	   a	   recording	   chamber	  with	   extracellular	   solution	   containing	  140mM	  NaCl,	  3mM	  KCl,	  1.5mM	  MgCl2,	  2.5mM	  CaCl2,	  11mM	  glucose,	  and	  10mM	  Hepes	  (305	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mOsm,	   pH	   7.4,),	   which	   was	   supplemented	   with	   TTX	   (1μM)	   to	   block	   action	  potentials,	   APV	   (50μM)	   to	   block	  NMDARs	   and	  bicuculline	   (20μM)	   to	   block	  GABAA	  receptor-­‐mediated	  mIPSCs.	  Whole	   cell	   voltage	   clamp	   recordings	   were	  made	   with	  patch	   pipettes	   filled	   with	   intracellular	   solution	   containing	   110mM	   Cs-­‐methanesulfonate,	   10mM	  CsCl,	   10mM	  Hepes,	   0.2mM	  EGTA,	   4mM	  Mg-­‐ATP,	   0.3mM	  Na2-­‐GTP,	   and	   10mM	   sodium	   phosphocreatine	   (295mOsm,	   pH	   7.4),	   with	   the	  membrane	   potential	   clamped	   at	   −70mV.	   Recordings	   started	   5	   minutes	   after	  establishing	   whole-­‐cell	   configuration	   to	   ensure	   equilibration	   between	   the	   pipette	  solution	  and	   the	  cytosol.	  mEPSCs	  were	  recorded	  with	  an	  Axopatch	  200B	  amplifier	  and	  displayed	  and	  recorded	  digitally	  on	  a	  computer	  for	  subsequent	  off-­‐line	  analysis	  with	  Clampfit.	  	  
	  
Data	  analysis.	  	  Immunocytochemistry.	   A	   double-­‐colored	   image	   (red	   from	   stained	   glutamate	  receptors	  and	  a	  DIC	   image	  for	  morphology)	  was	  separated	   into	  two	  channels	  with	  Image-­‐J	   software,	   and	   the	   two	  windows	  were	   synchronized.	  By	   tracing	  a	  neuron’s	  dendrites	  in	  the	  DIC	  channel,	  the	  corresponding	  postsynaptic	  AMPAR	  clusters	  were	  able	  to	  be	  precisely	  located	  in	  the	  red	  channel.	  AMPAR	  puncta	  size	  was	  calculated	  as	  the	   product	   of	   size	   and	   fluorescence	   intensity	   of	   each	   puncta.	   The	   data	   were	  presented	  as	  averages	  of	  AMPAR	  puncta	  ±	  SEM	  normalized	  to	  controls.	  Greater	  than	  100	  hundred	  puncta	  were	  measured	  per	  cell,	  and	  15-­‐20	  neurons	  were	  analyzed	  per	  experimental	  condition.	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Electrophysiology.	   Trace	   files	  were	  exported	   from	   the	  Clampex	   recording	   software	  and	   analyzed	   offline	   with	   Clampfit.	   	   Recordings	   were	   initially	   judged	   suitable	   for	  analysis	  based	  on	  comparison	  of	   the	  membrane	  seal	  before	  and	  after	  recording.	   If	  the	   seal	   deteriorated	   by	   more	   than	   15%,	   cells	   were	   discarded.	   Templates	   for	   a	  typical	   mEPSC	   were	   created	   using	   Clampfit	   software	   that	   averaged	   25	   manually	  selected	  typical	  events.	  The	  templates	  were	  used	  to	  scan	  the	  traces	  for	  events	  with	  highly	   similar	   kinetics	   and	   a	   moving	   baseline	   was	   created	   from	   each	   event	   to	  calculate	   amplitude.	   All	   data	   were	   presented	   as	   normalized	   mean	   ±	   SEM.	   The	  relationship	   between	   control	   and	   experimental	   amplitude	   and	   frequency	  distributions	  was	  determined	  by	  ranking	  values	  from	  all	  cells	  recorded	  from	  control,	  bicuculline,	   TTX,	   or	  TTX/Aβ	   treated	   cultures	   in	   ascending	   order.	   These	   amplitude	  distributions	   were	   linearly	   interpolated	   to	   produce	   an	   equal	   number	   of	  observations	  in	  each	  condition.	  	  To	  calculate	  the	  ratio	  of	  CpAMPAR	  current	  to	  total	  current,	  the	  amplitude	  of	  neurons	   recorded	  without	  PhTx	  was	   subtracted	   from	   the	   amplitude	  of	   recordings	  with	  PhTx	   and	  divided	  by	   the	   amplitude	  of	   recordings	  without	  PhTx.	  To	   compare	  normal	  GluA2	  containing	  currents	  the	  amplitude	  of	  recordings	  with	  PhTX	  was	  used.	  	  
Statistics.	  Analyses	  were	  performed	  using	  a	  two-­‐population	  Student’s	  t	  Test.	  	   	  
	  	   	  
21	  
CHAPTER	  THREE:	  RESULTS	  	  
A.	  Establishment	  of	  a	  neuronal	  HSP	  paradigm	  A	   reproducible	   paradigm	   was	   needed	   to	   produce	   homeostatic	   scaling	   of	  postsynaptic	  AMPAR	  amplitudes	  in	  response	  to	  changes	  in	  global	  neuronal	  activity.	  To	  inhibit	  action	  potentials	  in	  primary	  hippocampal	  neurons,	  voltage-­‐gated	  sodium	  ion	   channels	   were	   blocked	   with	   direct	   application	   of	   TTX	   to	   the	   culture	   media.	  Recordings	  were	  performed	  at	  various	   time	  points	   to	  determine	   the	  shortest	  drug	  incubation	  that	  could	  produce	  a	  significant	  homeostatic	  response.	  Lastly,	  bicuculline	  was	   applied	   to	   neuronal	   cultures	   to	   increase	   global	   network	   activity	   through	   the	  blockade	  of	  inhibitory	  GABAA	  receptors	  and	  produce	  the	  reciprocal	  downscaling	  of	  AMPARs	  (Figure	  2).	  	   TTX	  treated	  for	  24	  or	  48,	  but	  not	  12	  hours,	  produced	  a	  significant	  increase	  in	  the	   average	   amplitude	   of	   AMPAR-­‐mediated	   mEPSCs	   compared	   to	   control	   treated	  neurons	  (Control	  =	  1±0.087;	  12h	  TTX	  =	  1.14±0.096,	  p	  >	  0.05;	  24h	  TTX	  =	  1.35±0.096,	  p	  <	  0.01;	  48h	  TTX	  =	  1.46±0.130,	  p	  <	  0.01).	  Cells	  treated	  with	  bicuculline	  (BIC)	  for	  24	  hours	   showed	   a	   small	   but	   significant	   decrease	   in	   AMPAR-­‐mediated	   mEPSC	  amplitude	   compared	   to	   control	   treated	   cells	   (Control	   =	   1±0.086;	   24h	   BIC	   =	  0.80±0.098,	  p	  <	  0.05)	  (Figure	  2).	  	  	   No	  effect	  was	  seen	  in	  any	  of	  the	  treatment	  paradigms	  on	  mEPSC	  frequency,	  indicating	   that	   no	   change	   occurred	   via	   pre-­‐synaptic	   dynamics	   such	   as	   vesicle	  number	  and	   release,	  or	   in	   total	   synapse	  number.	  This	   suggests	   that	   the	  measured	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changes	  were	  indeed	  due	  to	  a	  postsynaptic	  scaling	  effect	  of	  surface	  AMPARs	  (Figure	  2).	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Figure	   2.	   Induction	   of	   HSP	   by	   activity	   deprivation.	   A.	   Sample	   traces	   showing	  AMPAR-­‐mediated	   mEPSCs	   after	   application	   of	   different	   channel	   antagonists.	   B.	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The	  effect	  of	  Aβ	  treatment	  on	  mEPSC	  amplitude	  during	  conditions	  of	  basal	  neuronal	  activity	  was	  investigated	  at	  various	  periods	  of	  time.	  When	  Aβ	  monomer	  was	  applied	  (0.5μM)	   directly	   to	   the	   culture	   medium	   for	   12,	   24,	   and	   48	   hours,	   a	   small	   but	  significant	   decrease	   in	   amplitude	   was	   observed	   at	   24	   and	   48	   hours	   (Control	   =	  1±0.076;	   Aβ	   24h	   =	   0.892±0.112,	   p	   <	   0.05;	   Aβ	   48h	   =	   0.916±0.129,	   p	   <	   0.05).	   Aβ	  treatment	   for	   12	   hours	   was	   not	   significantly	   different	   from	   control	   (Control	   =	  1±0.076;	  Aβ	  12h	  =	  0.0962±0.112,	  p	  >	  0.05)	  (Figure	  3).	  No	  change	  in	  frequency	  was	  observed	   when	   Aβ	   was	   applied	   for	   any	   length	   of	   time	   tested	   indicating	   that	   Aβ	  predominantly	  affected	  postsynaptic	  dynamics	  (Figure	  3).	  I	  found	  that	  neuronal	  treatment	  with	  TTX	  for	  24	  hours	  faithfully	  produced	  a	  robust	   scaling	   response	   in	   a	   relatively	   short	   period	   of	   time	   without	   the	   use	   of	  additional	  antagonists,	  and	  24-­‐hour	  treatment	  of	  Aβ	  showed	  a	  small	  and	  significant	  decrease	   in	   AMPAR-­‐mediated	   mEPSC	   amplitude,	   I	   therefore	   chose	   24	   hour	  treatments	  for	  all	  future	  studies.	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Figure	   3.	   Treatment	   with	   Aβ	   decreases	   postsynaptic	   AMPAR-­‐mediated	  














































































	  	   	  
26	  
C.	  Aβ	  enhances	  TTX-­‐mediated	  HSP	  Postynaptic	   decreases	   in	   AMPARs	   in	   the	   presence	   of	   Aβ	   (Figure	   2)	   is	   not	   a	   new	  finding,	   however,	   its	   effects	   during	   homeostatic	   responses	   to	   changes	   in	   global	  network	   activity	   has	   not	   been	   reported.	   Therefore,	   to	   test	   the	   effect	   of	   Aβ	   during	  activity	   deprivation,	   Aβ	  was	   co-­‐applied	   to	   neuronal	   cultures	   with	   TTX.	   As	   shown	  previously,	  Aβ	  alone	  produced	  a	  modest,	  but	  significant	  decrease	  in	  AMPAR	  mEPSC	  amplitude	   after	   24	   hour	   treatment.	   Interestingly,	   when	   neurons	   were	   co-­‐treated	  with	  Aβ	  and	  TTX	  together,	  the	  average	  amplitude	  of	  AMPAR-­‐mediated	  mEPSCs	  was	  not	  attenuated.	  In	  contrast,	  co-­‐treatment	  of	  TTX	  and	  Aβ	  showed	  a	  greater	  increase	  in	  mEPSC	  amplitude	  compared	  to	  TTX	  treatment	  alone	  (Control	  =	  1±0.079;	  24h	  Aβ=	  0.84±0.082,	  p	  <0.05;	  24	  h	  TTX	  =	  1.37±0.097,	  p	  <	  0.01;	  24h	  TTX/Aβ	  =	  1.59±0.102,	  p<	  0.005,	  p(vs.	  TTX)	  <	  0.05).	  This	   indicates	   that	  under	  conditions	  of	  activity	  deprivation,	  Aβ	   induces	   synaptic	   responses	  distinct	   from	   those	  under	   basal	   conditions	   (Figure	  4A,B).	  The	   increase	   in	  AMPAR	  amplitude	  was	  not	   accompanied	  by	  any	   changes	   in	  mEPSC	  frequency,	  indicating	  no	  changes	  in	  synapse	  number	  or	  presynaptic	  activity	  (Figure	  4C).	  A	  plot	  of	  the	  cumulative	  distribution	  of	  amplitudes	  across	  all	  treatments	  showed	  that	  co-­‐application	  of	  TTX/Aβ	  shifted	  the	  average	  amplitude	  of	  mEPSCs	  to	  the	  right.	  This	  data	  suggests	  that	  a	  uniform	  increase	  across	  synapses	  was	  detected,	  rather	  than	  a	  preferential	  scaling	  of	  a	  subset	  of	  neurons	  or	  synapses	  (Figure	  4C).	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D.	  HSP	  requires	  the	  PI3K/Akt	  signaling	  pathway	  	  The	  PI3K/	  Akt	   signaling	   pathway	   is	   required,	   but	   not	   up-­‐regulated,	   for	   inactivity-­‐dependent	  HSP	  and	  can	  be	  blocked	  with	  the	  application	  of	  a	  PI3K	  inhibitor	  (Hou	  et	  al.,	  2008).	  Therefore	  it	  is	  possible	  that	  activation	  of	  this	  pathway	  during	  TTX	  and	  Aβ	  co-­‐treatment	   could	   account	   for	   the	   enhanced	   AMPAR	   currents.	   The	   PI3K/Akt	  pathway	  is	  involved	  in	  protein	  synthesis	  and	  AMPAR	  membrane	  insertion	  and	  if	  up-­‐regulated	  during	  HSP	  could	  provide	  a	  mechanism	  for	  the	  increased	  accumulation	  of	  AMPARs	  at	  the	  synaptic	  membrane.	  To	  test	  this	  hypothesis,	  neurons	  were	  recorded	  after	   LY2940002	   (LY,	   20μM),	   a	   PI3K	   inhibitor,	   was	   co-­‐applied	   at	   the	   time	   of	  treatment.	   As	   predicted,	   LY	   inhibited	   the	   scaling	   up	   of	   AMPAR	  mEPSC	   amplitude	  after	   treatment	  with	  TTX	  alone.	   Interestingly,	  LY	  had	  no	  effect	  on	  neurons	   treated	  with	   Aβ	   alone,	   while	   neurons	   treated	   with	   TTX/Aβ	   showed	   a	   blockade	   of	   HSP	  (Control	  =	  1±0.073;	  Aβ	  =	  0.78±0.134,	  p	  <	  0.05;	  TTX	  =	  1.35±0.080,	  p	  <	  0.01;	  TTX/Aβ	  =	  1.64±0.065,	  p	  <	  0.001;	  TTX+LY	  =	  1.09±0.121,	  p	  >	  0.05;	  TTX/Aβ+LY	  =	  1.14±0.125,	  p	  >	   0.05).	   These	   results	   show	   that	   LY	   is	   sufficient	   to	   block	   both	   TTX	   and	   TTX/Aβ	  synaptic	  scaling	  back	  to	  control	  levels,	  indicating	  that	  the	  enhanced	  current	  with	  the	  co-­‐application	   of	   Aβ	   was	   not	   mediated	   via	   the	   PI3K/Akt	   pathway	   and	   that	   both	  conditions	   require	   the	   pathway	   to	   be	   active	   for	   scaling	   to	   occur.	   This	   data	   also	  suggests	  that	  enhancement	  was	  regulated	  via	  homeostatic	  mechanisms,	  rather	  than	  an	  alternate,	  unrelated	  increase	   in	  surface	  AMPARs,	  because	  application	  of	  LY	  was	  sufficient	  to	  prevent	  AMPAR	  increases	  in	  the	  TTX	  and	  Aβ	  co-­‐treated	  neurons.	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Western	  analysis	  using	  cells	  treated	  with	  TTX,	  Aβ,	  or	  TTX/Aβ	  for	  1,	  4	  and	  24	  hours	   showed	   no	   changes	   in	   phosphorylated	   Akt	   (pAkt)	   levels,	   a	   downstream	  substrate	  of	  PI3K,	  compared	  to	  control	  neurons	  (Figure	  5B).	  This	   finding	  supports	  that	   basal	   levels,	   but	   not	   enhanced	   PI3K/Akt	   activity	   are	   necessary	   for	   a	  homeostatic	  response.	  Of	  particular	  note,	   total	  Akt	   levels	  were	   increased	  when	  Aβ	  was	  treated	  alone	  or	  with	  TTX,	  possibly	  indicating	  that	  synaptic	  enhancement	  could	  be	  regulated	  via	  a	  PI3K	  independent	  mechanism	  through	  Akt.	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Figure	   5.	   PI3K	   activity	   is	   required	   for	   HSP	   but	   does	   not	   mediate	   the	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E.	  CpAMPAR	  signaling	  is	  necessary	  for	  HSP	  An	  increase	   in	  the	  expression	  of	  CpAMPARs	  at	   the	  synaptic	  surface	   is	  required	  for	  the	   initiation	   of	   the	   homeostatic	   response.	   From	   the	   data	   shown	   above,	   the	  PI3K/Akt	  pathway	  seems	  to	  be	  a	  permissive	  factor,	  rather	  than	  the	  initiator	  for	  HSP	  enhancement	   by	   Aβ.	   Although	   the	   exact	   mechanisms	   remain	   unclear,	   previous	  studies	   have	   shown	   that	   selective	   blockade	   of	   CpAMPARs	   inhibits	   a	   homeostatic	  scaling	  response,	  and	  that	   increased	  expression	  of	  these	  receptors	  is	  necessary	  for	  the	   homeostatic	   response	   to	   begin.	   To	   examine	   the	   role	   of	   CpAMPARs	   in	   the	   Aβ-­‐mediated	  enhancement	  of	  HSP,	  neurons	  were	  treated	  with	  TTX	  or	  TTX/Aβ,	  with	  the	  co-­‐application	   of	   the	   CpAMPAR	   selective	   antagonist,	   PhTx,	   for	   24	   hours.	   As	  predicted,	  blockade	  of	  CpAMPARs	  was	  sufficient	  to	  block	  the	  homeostatic	  response	  of	  treatment	  with	  TTX	  alone	  or	  with	  TTX/Aβ	  (Control	  =	  1±0.025;	  TTX	  =	  1.37±0.038,	  p	   <0.01;	   TTX/Aβ	   =	   1.70±0.048,	   p	   <	   0.001;	   TTX+PhTx	   =	   1.049±0.031,	   p	   >	   0.05;	  TTX/Aβ+PhTx	   =	   1.084±0.057,	   p	   >	   0.05)	   (Figure	   6).	   This	   data	   provided	   further	  evidence	   that	   increased	   expression	   and	   signaling	   through	   GluA2-­‐lacking	   AMPARs	  was	   necessary	   for	   HSP,	   and	   that	   Aβ-­‐mediated	   facilitation	   of	   HSP	   during	   activity	  deprivation	  was	  indeed	  working	  through	  homeostatic	  mechanisms..	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Figure	  6.	  HSP	   is	   occluded	  when	  PhTx	   is	   applied	   during	   scaling.	  Blockade	  of	  CpAMPARs	   is	  sufficient	   to	  occlude	  HSP.	  A.	  Sample	  traces	  of	  neurons	  recorded	  24	  hours	  after	  treatment	  with	  Aβ,	  TTX,	  or	  TTX/Aβ	  with	  or	  without	  the	  co-­‐application	  of	   PhTX	   to	   block	   all	   CpAMPARs.	   B.	   Plot	   of	   normalized	   amplitudes	   shows	   that	  blockade	  of	  CpAMPARs	  from	  the	  onset	  of	  changes	  in	  global	  activity	  is	  sufficient	  to	  block	  al	  homeostatic	   scaling.	  All	  values	  are	  normalized	   to	  control,	  error	  bars	  =	  ±	  SEM.	  Student’s	  paired	  two	  tailed	  t-­‐test,	  *	  =	  p	  <	  0.05,	  **	  =	  p	  <	  0.01,	  ***	  =	  p	  <	  0.001,	  ns	  =	  not	  significant.	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F.	  Aβ-­‐mediated	  enhancement	  of	  HSP	  increases	  GluA1	  surface	  expression	  Because	  HSP	  is	  expressed	  via	  increased	  accumulation	  of	  AMPARs	  at	  synaptic	  sites,	  I	  examined	  surface	  GluA1	  levels	  by	  immunocytochemistry	  to	  corroborate	  the	  changes	  observed	  in	  electrophysiology.	  	  An	  antibody	  specific	  for	  the	  N-­‐terminal	  extracellular	  region	   of	   the	   GluA1	   subunit	   was	   used	   under	   impermeant	   conditions	   to	   visualize	  surface	   expression	   of	   AMPARs.	   These	   immunostaining	   experiments	   showed	   a	  decrease	  in	  synaptic	  AMPARs	  when	  neurons	  were	  treated	  with	  Aβ,	  and	  an	  increase	  when	  treated	  with	  TTX,	  correlating	  with	  the	  previously	  reported	  changes	  in	  mEPSCs	  (Control	   =	   1±0.025;	   Aβ	   =	   0.92±0.024,	   p	   <	   0.05;	   TTX	   =	   1.18±0.026,	   p	   <	   0.0001.).	  Furthermore,	  GluA1	   surface	   levels	   showed	  a	   further	   increase	   in	   cells	   treated	  with	  TTX/Aβ	  compared	  to	  TTX	  alone	  (Control	  =	  1±0.025;	  TTX	  =	  1.18±0.026,	  p	  <	  0.0001;	  TTX/Aβ	   =	   1.34±0.028,	   p(control)	   <	   0.0001,	   p(TTX)	   <	   0.005),	   consistent	   with	   the	   Aβ-­‐mediated	  enhancement	  of	  HSP	  in	  mEPSC	  recordings	  (Figure	  7).	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G.	   Aβ	   application	   during	   activity	   deprivation	   increases	   the	   sensitivity	   of	  
mEPSCs	  to	  the	  selective	  CpAMPAR	  antagonist	  PhTx	  The	  data	  shown	  thus	  far	  has	  suggested	  that	  the	  enhancement	  of	  HSP	  during	  the	  co-­‐treatment	  with	  TTX	  and	  Aβ	  acts	  through	  homeostatic	  mechanisms.	  Therefore,	  we	  sought	  to	  characterize	  the	  enhanced	  mEPSC	  current	  in	  TTX/Aβ	  treated	  neurons	  by	  dissecting	  the	  contribution	  of	  normal	  AMPARs	  and	  CpAMPARs	  to	  the	  total	  current	  recorded.	  We	  hypothesized	  that	  the	  regulation	  of	  CpAMPAR	  expression	  was	  altered	  in	  Aβ	  and	  TTX	  co-­‐treated	  neurons.	  After	  initiation	  of	  HSP	  when	  there	  is	  a	  transient	  increase	  in	  CpAMPAR	  expression,	  Aβ-­‐treated	  neurons	  may	  continue	  inserting	  CpAMPARs	  at	  the	  surface,	  subsequently	  driving	  a	  larger	  HSP	  response.	  Alternatively,	  after	  the	  initial	  increase	  in	  CpAMPAR	  expression,	  the	  internalization	  of	  existing	  CpAMPARs	  is	  attenuated	  and	  they	  are	  left	  at	  the	  surface.	  Leftover	  or	  increased	  expression	  of	  CpAMPARs	  could	  therefore	  account	  for	  the	  enhanced	  current.	  To	  investigate	  this	  hypothesis,	  neurons	  were	  treated	  with	  TTX	  alone	  or	  TTX/Aβ	  as	  aforementioned,	  for	  8	  or	  24	  hours	  to	  allow	  AMPAR-­‐mediated	  HSP.	  Recordings	  of	  mEPSCs	  were	  then	  conducted	  when	  PhTx	  was	  added	  only	  during	  the	  time	  of	  recording,	  therefore	  allowing	  the	  measurement	  of	  the	  CpAMPAR	  component	  after	  HSP	  occurred.	  	  	   Experiments	  were	  performed	  8	  hours	  after	  the	  treatment	  of	  TTX	  ±	  Aβ	  to	  determine	  if	  CpAMPAR-­‐mediated	  current	  could	  be	  observed	  earlier	  in	  TTX/Aβ	  treated	  neurons.	  Recordings	  of	  mEPSCs	  showed	  that	  cells	  treated	  with	  Aβ	  during	  activity	  deprivation	  did	  not	  show	  a	  difference	  in	  the	  time	  of	  onset	  of	  CpAMPAR	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current,	  compared	  to	  TTX	  treatment	  alone	  (Control	  8hrs	  =	  1±0.023;	  TTX	  8hrs	  =	  1.12±0.012,	  p	  <	  0.05;	  TTX/Aβ	  8hrs	  =	  1.10±0.036,	  p	  <	  0.05,	  p(TTX	  8hr	  vs	  TTX/Aβ	  8hr)	  >	  0.05).	  The	  increase	  in	  amplitude	  for	  both	  TTX	  and	  TTX/Aβ	  treated	  neurons	  at	  the	  8	  hour	  time	  point	  was	  predominantly	  mediated	  via	  CpAMPARs,	  as	  application	  of	  PhTx	  to	  during	  these	  recordings	  was	  sufficient	  to	  return	  mEPSC	  ampltudes	  to	  levels	  similar	  to	  control	  (Control	  8hrs	  =	  1±0.023;	  TTX	  8hrsàPhTx	  	  =	  0.98±0.049,	  p	  >	  0.05;	  TTX/Aβ	  8hrsàPhTx	  =	  1.01±0.033,	  p	  >	  0.05).	  This	  data	  suggests	  that	  the	  Aβ-­‐induced	  enhancement	  of	  HSP	  is	  not	  due	  to	  an	  earlier	  onset	  of	  the	  homeostatic	  response	  and	  that	  both	  conditions	  showed	  a	  typical	  increase	  in	  CpAMPARs	  during	  the	  early	  stages	  of	  HSP	  (Figure	  8A,B).	  	  	   Neurons	  that	  were	  treated	  with	  TTX	  for	  24	  hours	  and	  then	  recorded	  in	  the	  presence	  of	  PhTx	  showed	  a	  decrease	  in	  mEPSC	  amplitude	  with	  the	  blockade	  of	  CpAMPARs	  (Control	  24	  hrs	  =	  1±0.052;	  TTX	  24	  hrs	  =	  1.36±0.026,	  p	  <	  0.01,	  TTX	  24hrsàPhTx	  =	  1.18,	  ±0.063,	  p	  <	  0.05),	  suggesting	  that	  the	  elevated	  surface	  expression	  of	  CpAMPARs	  was	  still	  present	  in	  these	  cells	  (Figure	  8A,B).	  Interestingly,	  neurons	  treated	  with	  TTX/Aβ	  showed	  that	  after	  enhancement	  of	  HSP,	  there	  was	  a	  larger	  CpAMPAR	  component	  that	  could	  be	  blocked	  by	  PhTx	  (Control	  24	  hrs	  =	  1±0.0525;	  TTX	  24	  hrs	  =	  1.36±0.026,	  p	  <	  0.01;	  TTX	  24hrsàPhTx	  =	  1.18,	  ±0.063,	  p	  <	  0.05;	  TTX/Aβ	  24	  hrs	  =	  1.79±0.054,	  p	  <	  0.001;	  TTX/	  Aβ	  24hrsàPhTx	  =	  1.49±0.044,	  p<	  0.01).	  This	  finding	  suggests	  an	  increased	  expression	  of	  CpAMPARs	  at	  the	  surface	  with	  the	  co-­‐application	  of	  Aβ	  compared	  to	  TTX	  treatment	  alone	  (Figure	  8A,B).	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A	  ratio	  of	  CpAMPAR	  current	  to	  total	  AMPAR	  current	  showed	  more	  CpAMPAR	  expression	  after	  Aβ	  treatment	  during	  activity	  deprivation,	  which	  consequently	  contributed	  a	  larger	  percentage	  to	  the	  total	  activity	  during	  synaptic	  transmission	  (Control	  =	  0.042±0.016;	  TTX	  =	  0.157±0.007,	  p(vs.	  control)	  <	  0.01;	  TTX/Aβ	  =	  0.191±0.005,	  p(vs.	  control)	  <	  0.001,	  p(vs.	  TTX)	  <	  0.05)	  (Figure	  8D).	  A	  comparison	  of	  the	  normal	  calcium-­‐impermeable	  AMPAR	  currents	  also	  showed	  a	  significant	  increase	  in	  TTX/Aβ	  compared	  to	  TTX	  treated	  neurons	  (Figure	  8C.	  TTXàPhTx	  24hrs	  =	  1.18,	  SE	  =	  0.063,	  n	  =	  5,	  p(vs.	  control)	  <	  0.01;	  TTX/Aβ	  24hrsàPhTx	  =	  1.49,	  SE	  =	  0.044,	  n	  =	  5,	  p(vs.	  
control)	  <	  0.001.	  p(vs	  TTX)	  <	  0.01).	  An	  increase	  in	  typical	  AMPAR	  expression	  may	  have	  been	  induced	  by	  the	  higher	  expression	  of	  CpAMPARs,	  however,	  further	  investigation	  would	  be	  required	  to	  determine	  this	  link.	  These	  results	  indicate	  that	  both	  CpAMPAR	  and	  normal	  GluA2-­‐containing	  AMPARs	  are	  up-­‐regulated	  during	  the	  Aβ-­‐mediated	  enhancement	  of	  HSP	  during	  activity	  deprivation,	  but	  the	  CpAMPAR	  component	  is	  higher	  in	  TTX/Aβ	  compared	  to	  TTX	  treated	  neurons.	  	  	   	  





















































































































































































































































Figure	  8.	  CpAMPAR	  and	  normal	  AMPAR	  surface	  expression	  are	  increased	  
after	  TTX-­‐mediated	  HSP	  in	  the	  presence	  of	  Aβ.	  A.	  Sample	  traces	  of	  mEPSCs	  after	   8	   or	   24	   hour	   application	   of	   the	   indicated	   treatments.	  B.	   Plots	   showing	  normalized	  values	  of	  average	  mEPSC	  amplitudes.	  PhTx	  was	  only	  applied	  to	  the	  extracellular	  recording	  solution	  at	  the	  time	  of	  the	  experiment.	  C.	  Plot	  of	  GluA2	  containing	  currents	  (currents	  after	  application	  of	  PhTx).	  D.	  Plot	  of	  the	  ratio	  of	  CpAMPAR	  current	   to	   total	  AMPAR	  current.	  Ratio	  =	   (amplitude	  without	  PhTx-­‐	  amplitude	   with	   PhTx)/	   (amplitude	   without	   PhTx).	   Values	   normalized	   to	  control.	  Student’s	  paired	  two	  tailed	  t-­‐test,	  **	  =	  p	  <	  0.01,	  ***	  p	  <	  0.001;	  TTX	  vs.	  
TTX/Aβ:	  #	  =	  p	  <	  0.05,	  ##	  =	  p	  <	  0.01;	  error	  bars	  =	  ±SEM.	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H.	  Enhanced	  HSP	  increases	  neuronal	  vulnerability	  during	  glutamate	  challenge	  TTX/Aβ	   treatment	   enhances	   HSP	   and	   induces	   an	   increase	   in	   the	   expression	   of	  CpAMPARs.	  These	  receptors	  have	  been	  linked	  to	  neuronal	  injury	  in	  conditions	  such	  as	  ALS	  and	  ischemia	  and	  therefore	  may	  provide	  insight	  into	  how	  dysregulated	  HSP	  by	   Aβ	   may	   lead	   to	   synaptic	   deficits	   and	   neurodegeneration	   observed	   in	   AD.	  Additionally,	  an	  HSP	  response	  that	  overcompensates,	  as	  shown	  when	  Aβ	  is	  present	  during	   activity	   deprivation,	   would	   presumably	   leave	   neurons	   in	   a	  more	   excitable	  state	  with	  higher	  total	  surface	  expression	  levels	  of	  AMPARs.	  Neuronal	  networks	  that	  have	  an	  elevated	  level	  of	  excitability	  would	  then	  be	  prone	  to	  injury	  during	  periods	  of	  high	  activation.	  To	  investigate	  this	  hypothesis,	  neuronal	  viability	  was	  investigated	  in	  a	   cellular	   death	   assay	   after	   1	   hour	   of	   glutamate	   challenge	   (30μM).	   Cell	   death	  was	  analyzed	   after	   homeostatic	   scaling	   by	   quantifying	   the	   percentage	   of	   propidium	  iodide	  positive	  nuclei	  before	  and	  after	  glutamate	  application.	  Neurons	  treated	  with	  TTX	   alone	   displayed	   increased	   cell	   death	   compared	   to	   control	   conditions	   after	  glutamate	  challenge,	  presumably	  due	  to	  the	  elevated	  surface	  expression	  of	  AMPARs	  Importantly,	   neuronal	   cell	   death	   was	   further	   increased	   with	   TTX/Aβ	   treatment	  (Control	  =	  7.07±1.41;	  TTX	  =	  11.33±1.62,	  p	  <	  0.01,	  TTX/Aβ	  =	  13.98±1.79,	  p	  <	  0.001).	  Aβ	   application	   alone	   caused	   a	   small	   decrease	   in	   the	   percentage	   of	   dead	   cells,	  correlating	   with	   the	   previously	   shown	   reduced	   surface	   expression	   of	  AMPARs(Control	   =	   7.07±1.41;	   Aβ	   =	   5.11±0.72,	   p	   <0.05).	   This	   data	   suggests	   that	  enhanced	  HSP	  induced	  by	  the	  co-­‐application	  of	  Aβ	  during	  activity	  deprivation	  may	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push	  neurons	  to	  a	  more	  vulnerable	  state	  during	  periods	  of	  high	  synaptic	  activation.	  (Figure	  9).	  	  Homeostatic	   regulation	   has	   been	   identified	   in	   a	   variety	   of	   systems	   and	   is	  attracting	   a	   growing	   amount	   of	   interest.	   However,	   the	   underlying	   molecular	  mechanisms	   are	   largely	   unknown.	   Calcium	   has	   been	   implicated	   as	   a	   critical	  component	   for	   the	   initiation	   of	   HSP,	   and	   in	   contrast	   to	   Hebbian	   plasticity,	  homeostatic	  regulation	  is	  NMDAR	  independent,	  suggesting	  a	  novel	  route	  of	  calcium	  signaling.	   To	   test	   if	   increased	   CpAMPAR	   expression	   contributes	   to	   increased	  excitotoxicity	   after	   glutamate	   challenge,	   neurons	  were	   treated	  with	   the	  CpAMPAR	  selective	  antagonist,	  PhTx	   (2μM),	  during	   the	  glutamate	   treatment.	  PhTx	   treatment	  showed	  a	  trend	  for	  protection	  against	  glutamate	  challenge	  in	  both	  TTX/Aβ	  and	  TTX	  treatment	   alone.	   Both	   of	   these	   conditions	   showed	   higher	   levels	   of	   cell	   death	  compared	   to	   control	   neurons,	   presumably	   because	   after	   HSP	   they	   would	   have	  higher	  AMPAR	  surface	  expression	  and	  therefore	  greater	  activation	  of	  NMDARs	  upon	  glutamate	   application.	   Combined	   with	   the	   previous	   data	   showing	   elevated	  CpAMPAR	  expression,	   these	   results	   suggest	   that	  decreased	  neuronal	   viability	  may	  be	  caused	  by	   the	  prolonged	  expression	  of	  CpAMPARs	  (Control	  =	  7.07±1.41;	  TTX	  =	  11.33±1.62,	  p	  <	  0.05,	  TTX	  /Aβ	  =	  13.98±1.79,	  p	  <	  0.01;	  TTX	  +	  PhTx	  =	  10.52±1.26,	  p	  >	  0.05;	   TTX	   /Aβ	   +	   PhTx	   =	   9.44±1.61,	   p	   >	   0.05).	   A	   trend	   of	   increased	   cell	   death	   in	  TTX/Aβ	  treated	  cells	  compared	  to	  TTX	  alone	  was	  observed	  but	  it	  was	  not	  significant	  (TTX	  =	  11.33±1.62;	  TTX/Aβ	  =	  13.98±1.79,	  p>	  0.05).	  These	  findings	  suggest	  that	  Aβ	  enhances	   the	   increase	   of	   GluA2-­‐lacking	   and	   GluA2-­‐containing	   AMPARs	   after	   HSP,	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therefore	  during	  glutamate	  challenge	  there	  is	  more	  postsynaptic	  depolarization	  and	  NMDAR	   activation	   (Figure	   9).	   TTX/Aβ	   treated	   cells	   would	   have	   calcium	   influx	  through	  NMDARs	  and	  CpAMPARs,	  possibly	  increasing	  their	  vulnerability	  to	  elevated	  glutamate	  levels	  in	  AD.	  CpAMPARs	  have	  a	  very	  low	  expression	  profile	  during	  basal	  conditions,	  therefore	  PhTx	  treatment	  had	  little	  effect	  on	  cell	  death	  in	  control	  treated	  neurons.	  (Control	  =	  7.07±1.41;	  PhTx	  =	  7.15±1.36,	  p	  >	  0.05).	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CHAPTER	  FOUR:	  DISCUSSION	  	  
	  
Aβ	  application	  during	  activity	  deprivation	  enhances	  HSP	  This	   research	   demonstrates	   that	   Aβ	   differentially	   regulates	   synaptic	   plasticity	  during	  changes	  in	  global	  neuronal	  activity	  levels.	  Specifically,	  Aβ	  application	  leads	  to	  an	   enhancement	   in	   HSP	   during	   global	   activity	   deprivation.	   Additionally,	   Aβ	  treatment	   during	   periods	   of	   homeostatic	   synaptic	   scaling	   increases	   the	   surface	  expression	  of	  both	  GluA2-­‐lacking	  and	  GluA2-­‐containing	  AMPARs,	  which	  in	  turn	  may	  provoke	   neurons	   into	   a	   more	   susceptible	   state	   during	   excitotoxic	   challenge,	  eventually	   resulting	   in	   increased	   neuronal	   death.	   Homeostatic	   synaptic	   scaling	  requires	  the	  PI3K/Akt	  pathway,	  however	  it	  is	  not	  up-­‐regulated	  during	  Aβ-­‐mediated	  facilitation	   of	   HSP.	   Data	   presented	   here	   also	   suggests	   that	   the	   increased	   mEPSC	  amplitudes	   are	   not	   due	   to	   an	   earlier	   onset	   of	   the	   scaling	   response,	   and	   that	   the	  increased	   current	   is	   more	   sensitive	   to	   the	   selective	   CpAMPAR	   antagonist,	   PhTx.	  Decreased	   glutamate	   transporter	   expression	   has	   been	   reported	   in	   AD	   to	   produce	  neurotoxicity	  via	  an	  excess	  of	  glutamate	  leftover	  in	  the	  synaptic	  cleft.	  Here,	  I	  showed	  that	   a	   glutamate	   challenge	   produced	   increased	   neuronal	   death	   after	   the	   Aβ-­‐mediated	  enhancement	  of	  HSP.	  These	   findings	  provide	  evidence	   that	  dysregulated	  homeostatic	  synaptic	  responses	  and	  increased	  CpAMPAR	  expression	  may	  play	  a	  key	  role	  in	  the	  initial	  dysfunction	  in	  early	  stage	  AD,	  and	  may	  lead	  to	  the	  later	  observed	  synaptic	  defects	  and	  neurodegeneration.	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The	   excessive	   accumulation	   of	   Aβ	   in	   the	   brain	   has	   been	   shown	   to	   play	   a	  causal	  role	  in	  AD	  (Abbott	  and	  Nelson,	  2000;	  Glenner	  and	  Wong,	  2012;	  Tanzi,	  2005;	  Tanzi	   and	   Bertram,	   2005;	   Walsh	   et	   al.,	   2002).	   Aβ	   has	   been	   associated	   with	   a	  decrease	   in	   glutamatergic	   synaptic	   transmission,	   presumably	   through	   the	  endocytosis	  of	  AMPARs	  and	   the	  subsequent	  retraction	  of	  dendritic	   spines	   (Hsia	  et	  al.,	  1999;	  Hsieh	  et	  al.,	  2006b;	  Kamenetz	  et	  al.,	  2003;	  Shankar	  et	  al.,	  2007;	  Walsh	  et	  al.,	   2002).	   Transgenic	   mice	   overexpressing	   human	   APP	   (hAPP),	   with	   subsequent	  overproduction	   of	   Aβ,	   show	   severe	   AD-­‐like	   abnormalities,	   including	   amyloid	  plaques,	  neuritic	  dystrophy,	  deficits	   in	   learning	  and	  memory,	  as	  well	  as	   functional	  and	  structural	  synaptic	  deficits	  (Chin	  et	  al.,	  2005;	  Chin	  et	  al.,	  2004;	  Götz	  et	  al.,	  2004;	  Kobayashi	  and	  Chen,	  2005;	  Palop	  et	  al.,	  2005;	  Palop	  et	  al.,	  2003).	  Previous	  findings	  have	  shown	  that	  oligomeric	  Aβ	  induces	  a	  decrease	  in	  the	  surface	  levels	  of	  GluA1	  and	  PSD-­‐95	  (Almeida	  et	  al.,	  2005;	  Gu	  et	  al.,	  2009;	  Zhang	  et	  al.,	  2011)	  as	  well	  as	  GluA2	  in	  an	  NMDAR	  and	  Cdk-­‐5	  dependent	  pathway	   (Roselli	   et	   al.,	   2005).	   It	   is	   important	   to	  note	  however,	  that	  these	  studies	  investigated	  the	  role	  of	  AMPAR	  surface	  expression	  in	   the	   presence	   of	   Aβ	   during	   basal	   neuronal	   activity	   levels,	   or	   acute	   localized	  Hebbian	   plasticity,	   whereas	   changes	   in	   receptor	   surface	   expression	   levels	   during	  chronic	  global	  changes	  in	  network	  activity	  have	  yet	  to	  be	  reported.	  Using	  a	  computational	  approach	  to	  model	  neuronal	  networks	  in	  AD,	  in	  which	  networks	  can	  be	  trained	  to	  learn	  and	  store	  memories	  in	  a	  manner	  similar	  to	  conditions	  occurring	  in	  vivo,	  it	  has	  been	  demonstrated	  that	  synaptic	  dysfunction	  can	  lead	  to	  severe	  memory	  loss	  and	  cognitive	  decline	  (Hopfield,	  1982;	  Ruppin	  and	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Reggia,	  1995).	  The	  loss	  of	  synapses	  in	  an	  artificial	  neural	  network	  can	  cause	  memory	  loss,	  however,	  the	  pattern	  of	  cognitive	  decline	  does	  not	  mimic	  that	  seen	  in	  AD	  (Small,	  2008).	  In	  these	  models,	  memories	  are	  often	  	  retained	  until	  a	  critical	  amount	  of	  synaptic	  loss	  is	  reached,	  in	  which	  memory	  loss	  is	  produced	  in	  a	  sudden	  and	  catastrophic	  manner.	  However,	  memory	  loss	  is	  gradual	  in	  AD,	  in	  which	  recent	  memories	  are	  typically	  lost	  first	  and	  older,	  more	  consolidated	  memories,	  remain	  intact	  until	  the	  disease	  progresses	  (Garcia-­‐Ptacek	  et	  al.,	  2013).	  To	  mimic	  the	  pattern	  of	  amnesia	  observed	  in	  AD	  patients,	  a	  mechanism	  of	  synaptic	  compensation,	  or	  scaling,	  needs	  to	  be	  present	  within	  neuronal	  networks	  (Small,	  2004,	  2008).	  In	  an	  AD	  scaling	  model,	  the	  loss	  of	  input	  at	  a	  particular	  synapse	  could	  be	  balanced	  for	  by	  an	  increase	  in	  signaling	  at	  other	  synapses	  as	  the	  strength	  of	  synaptic	  inputs	  decreases	  (Ruppin	  and	  Reggia,	  1995).	  With	  a	  compensation	  from	  synaptic	  scaling	  introduced	  into	  the	  model,	  the	  artificial	  network	  can	  reproduce	  the	  gradual	  cognitive	  decline	  seen	  in	  AD	  (Small,	  2008),	  further	  providing	  strong	  evidence	  that	  synaptic	  scaling	  is	  indeed	  an	  important	  phenomenon	  in	  AD.	  	  	  
Elevated	   levels	   of	   Aβ	   are	   implicated	   with	   increased	   seizure	   and	   epileptic	  
activity	  Neurons	   from	  AD	  mouse	  models	  have	  the	  most	  noticeable	   impairments	   in	  regions	  like	   the	   dentate	   gyrus	   (DG),	   an	   integral	   area	   in	   the	   hippocampus	   involved	   in	  learning	  and	  memory.	  Aβ-­‐induced	  deficits	   in	  hippocampal	  dependent	   learning	  and	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memory	  correlate	  with	  alterations	   in	  calcium	  and	  synaptic	  activity	   in	  granule	  cells	  within	  the	  DG	  (Chin	  et	  al.,	  2005;	  Palop	  et	  al.,	  2005;	  Palop	  et	  al.,	  2003).	  Interestingly,	  many	  of	  the	  observable	  changes	  in	  the	  DG	  have	  not	  only	  been	  observed	  in	  humans	  with	  AD	   (Palop	   et	   al.,	   2003),	   but	   also	   in	   epilepsy	   (Nägerl	   et	   al.,	   2000)	   and	   animal	  models	  of	  abnormal	   increases	  in	  excitatory	  activity	  (Marksteiner	  et	  al.,	  1990;	  Peng	  and	  Houser,	   2005;	   Tonder	   et	   al.,	   1994).	   These	   findings	   have	   shown	   that	   synaptic	  alterations	  seen	  in	  transgenic	  hAPP	  mice	  and	  human	  AD	  patients	  may	  be	  caused	  by	  aberrant	   increases	   in	   neuronal	   activity,	   which	   is	   consistent	   with	   the	   observed	  increased	  risk	  for	  seizure	  activity	  in	  both	  sporadic	  and	  familial	  AD	  (Amatniek	  et	  al.,	  2006;	  Hesdorffer	  et	  al.,	  1996;	  Marksteiner	  et	  al.,	  1990;	  Mattson	  et	  al.,	  1992;	  Mendez	  and	  Lim,	  2003).	  Correlating	   with	   an	   increased	   HSP	   response	   reported	   here,	   Palop	   et	   al.	  (2007)	  demonstrated	  that	  increased	  levels	  of	  Aβ	  produced	  in	  hAPP	  transgenic	  mice	  increased	  spontaneous	  non-­‐convulsive	  seizure	  activity	  in	  cortical	  and	  hippocampal	  networks,	   indicating	   that	   the	   net	   overall	   effect	   of	   Aβ	   in	   these	   networks	   was	  excitatory.	   Indeed,	   AD	   patients	   also	   have	   a	   higher	   incidence	   of	   seizures	   than	  reference	  populations	  (Amatniek	  et	  al.,	  2006;	  Hauser	  et	  al.,	  1986;	  Hesdorffer	  et	  al.,	  1996;	  Lozsadi	  and	  Larner,	  2006;	  Mendez	  and	  Lim,	  2003),	  and	   the	  risk	  of	  epileptic	  activity	   in	   the	   early	   stages	   of	   AD	   is	   very	   high	   in	   patients	   showing	   early	   onset	  dementia:	   with	   an	   87-­‐fold	   increase	   in	   seizure	   incidences	   compared	   to	   an	   age	  matched	   control	   population	   (Amatniek	   et	   al.,	   2006;	   Mendez	   et	   al.,	   1994).	   Hyper-­‐excitable	  neuronal	  networks	  in	  an	  AD	  brain	  may	  seem	  contradictory	  given	  previous	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findings	   that	   exposure	   to	   increased	   levels	   of	   Aβ	   decreases	   postsynaptic	   AMPAR	  accumulation	   and	   leads	   to	   the	   eventual	   deterioration	   of	   spines	   and	  neurodegeneration	   (Hsia	   et	   al.,	   1999;	  Kamenetz	   et	   al.,	   2003;	   Shankar	   et	   al.,	   2007;	  Walsh	   and	   Selkoe,	   2004b).	   Early	   changes	   in	   physiology	   may	   produce	   over-­‐compensatory	   effects	   in	   homeostatic	   mechanisms	   however,	   thereby	   producing	  hyper-­‐excitable	  networks	   that	  over	   time	  show	  decreases	   in	  surface	  AMPAR	   levels,	  spine	  retraction	  and	  neuronal	  loss	  due	  to	  excitotoxic	  injury.	  A	  depletion	  of	  calcium	  and	  synaptic	  activity	  related	  proteins	  are	  observed	  in	  the	   hippocampus	   of	  AD	   transgenic	  mice,	  which	   could	   result	   in	   the	   suppression	   of	  global	  network	  activity.	  In	  a	  state	  of	  activity	  deprivation,	  neurons	  in	  the	  presence	  of	  Aβ	  could	  respond	  in	  an	  over-­‐compensatory	  scaling	  up	  of	  postsynaptic	  receptors	  in	  the	   early	   stages	   of	   AD.	   The	   enhanced	   homeostatic	   response	  may	   elevate	   network	  activity	   to	   levels	  observed	   in	   the	  early	   stages	  of	  AD,	  and	  may	  represent	   the	   initial	  aberrations	   in	   the	  disease	  pathology.	  Therefore,	   alterations	   in	  HSP	   could	   result	   in	  later	   onset	   neurodegeneration	   and	   synaptic	   loss	   commonly	   associated	   with	   AD.	  These	   findings	   are	   important	   because	   the	   current	   models	   used	   to	   study	   AD	   are	  typically	   focused	   on	   late-­‐stage	   phenotypes,	   which	   could	   result	   from	   earlier	  aberrations	  in	  homeostatic	  scaling	  responses.	  Further	  elucidation	  of	  Aβ’s	  regulation	  of	   HSP	   could	   therefore	   yield	   a	   better	   understanding	   of	   the	   disease	   pathogenesis,	  with	  the	  possibility	  that	  therapeutic	  intervention	  during	  these	  stages	  could	  produce	  treatments	  in	  the	  clinical	  setting.	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CpAMPAR	  expression	  in	  HSP	  AMPARs	  mediate	  the	  majority	  of	  rapid	  postsynaptic	  excitatory	  transmission	   in	  the	  brain	  and	  are	  generally	  calcium	  impermeable.	  AMPARs	  lacking	  a	  GluA2	  subunit	  are	  calcium	  permeable	   and	   recent	   studies	   have	   shown	  a	   growing	   amount	   of	   evidence	  that	   these	   special	   channels	   may	   be	   important	   contributors	   to	   neuronal	   injury	   in	  conditions	   such	   as	   ischemia	   and	   ALS.	   The	   research	   presented	   here	   showed	   an	  increase	   not	   only	   in	   typical	   GluA2-­‐containing	   AMPARs	   but	   also	   in	   the	   amount	   of	  GluA2-­‐lacking,	  CpAMPARs.	  These	  receptors	  can	  express	  themselves	  as	  GluA1/GluA3	  heterotetramers	   or	   GluA1	   homomers,	   both	   permitting	   calcium	   conductance.	  Importantly,	  recordings	  in	  the	  presence	  of	  PhTx	  showed	  that	  currents	  from	  TTX/Aβ	  treated	   neurons	   were	   more	   sensitive	   to	   PhTx,	   and	   the	   ratio	   of	   PhTx	   sensitive	  current	  to	  total	  current	  was	  increased	  after	  synaptic	  scaling	  in	  the	  presence	  of	  Aβ,	  indicating	   that	   CpAMPARs	   played	   a	   larger	   role	   in	   synaptic	   transmission	   in	   these	  neurons.	  	  This	  finding	  could	  be	  the	  result	  of	  a	  number	  of	  different	  contributing	  factors.	  First,	   Aβ	   could	   down-­‐regulate	   post-­‐translational	   levels	   of	   the	   GluA2	   subunit,	  therefore	   a	   larger	   percentage	   of	   inserted	   receptors	   after	   activity	   deprivation	   are	  calcium	   permeable	   (GluA2-­‐lacking),	   leading	   to	   a	   larger	   response.	   In	   this	   case,	   the	  response	   should	   be	   larger	   when	   recording	   after	   shorter	   periods	   of	   activity	  deprivation	   because	   neurons	   treated	   with	   TTX/Aβ	   would	   presumably	   have	  undergone	  synaptic	  scaling	  for	  longer	  periods	  of	  time	  than	  those	  treated	  with	  TTX	  alone.	  This	  was	  not	   found	   to	  be	   the	  case,	  as	   recordings	  after	  8	  hours	  of	   treatment	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showed	  no	  significant	  increase	  in	  synaptic	  scaling	  when	  neruons	  had	  Aβ	  co-­‐applied	  with	  TTX.	  Another	   conceivable	  mechanism	   is	   that	  Aβ	  application	  dysregulates	   the	  acute	   expression	   of	   GluA2-­‐lacking	   receptors	   at	   the	   initiation	   of	  HSP.	   If	   Aβ	   treated	  neurons	   had	   less	   CpAMPAR	   internalization	   after	   the	   initiation	   of	   the	   homeostatic	  response,	   these	   leftover	   receptors	   at	   the	   surface	   could	   account	   for	   the	   enhanced	  current	  and	  higher	  CpAMPAR	  expression	  observed.	   In	   this	  situation,	   the	   increased	  current	   amplitudes	  would	  be	  attributed	   to	   the	   leftover	  CpAMPARs	  at	   the	   synaptic	  surface.	  These	  elevated	  currents	  should	  be	  more	  sensitive	  to	  the	  selective	  CpAMPAR	  antagonist	   PhTx,	   which	   indeed	   was	   shown.	   Therefore,	   this	   research	   provides	  evidence	   that	   exposure	   to	   Aβ	   may	   lengthen	   the	   time	   of	   CpAMPAR	   surface	  expression	  after	  the	  initiation	  of	  HSP.	  It	  is	  important	  to	  note	  that	  mEPSC	  amplitudes	  in	   the	   presence	   of	   PhTx	  were	   still	   significantly	   higher	   in	  TTX/Aβ	   treated	   cultures	  compared	  to	  TTX	  treatment	  alone.	  This	  provides	  evidence	  that	  although	  CpAMPAR	  surface	   expression	   is	   increased,	   normal	   GluA2-­‐containing	   receptors	   are	   also	   up-­‐regulated	   at	   the	   surface.	   Whether	   total	   surface	   AMPAR	   levels	   are	   increased	   as	   a	  result	   of	   an	   extended	   period	   of	   CpAMPAR	   expression,	   or	   whether	   both	   receptor	  types	   are	   up-­‐regulated	   independently	   remains	   to	   be	   elucidated.	   Future	   studies	  should	   focus	   on	   the	   molecular	   mechanisms	   involved	   in	   the	   increased	   AMPAR	  surface	   insertion,	  namely	  whether	   it	   is	  mediated	   through	  altered	  receptor	  subunit	  insertion	   and	   internalization.	   Labeling	   surface	   GluA1	   and	   GluA2	   subunits	   and	  following	   their	   trafficking	   could	   shed	   light	   on	   whether	   specific	   subunits	   are	  trafficked	  differently	  during	  activity	  deprivation	  in	  the	  presence	  of	  Aβ.	  Additionally,	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recordings	  and	  receptor	  surface	  staining	  after	  HSP	  performed	  in	  the	  presence	  of	  a	  protein	   synthesis	   inhibitor	   such	   as	   anisomyocin,	   may	   elucidate	   the	   role	   of	   new	  protein	   synthesis	   in	   the	   homeostatic	   response	   and	   its	   regulation	   in	   the	   AD	  paradigm.	   One	   might	   hypothesize	   that	   GluA2	   subunits	   are	   preferentially	  internalized	   with	   the	   co-­‐treatment	   of	   TTX/Aβ,	   or	   GluA1	   subunits	   show	   higher	  synthesis	  and	  insertion	  into	  the	  membrane	  during	  HSP.	  	  
Calcium	  signaling	  and	  neuronal	  death	  Mechanisms	   of	   excitotoxic	   neuronal	   injury	   are	   complex	   and	   have	   yet	   to	   be	   fully	  elucidated.	  With	   increases	   in	   intracellular	  Ca2+,	  neuronal	  mitochondria	  take	  up	  the	  Ca2+	   causing	   a	   generation	   of	   reactive	   oxygen	   species	   and	   release	   of	   apoptotic	  mediators	   such	   as	   Cytochrome	   C.	   With	   a	   slower,	   less	   dramatic	   increase	   in	  intracellular	   Ca2+,	   neuronal	   damage	   is	   mediated	   via	   mechanisms	   such	   as	   the	  generation	   of	   nitric	   oxide	   with	   subsequent	   activation	   of	   poly(ADP-­‐ribose)	  polymerase	  (PARP)	  and	  release	  of	  mitochondrial	  apoptosis	  inducing	  factor	  (Hong	  et	  al.,	  2004).	  Therefore	  with	  more	  CpAMPAR	  expression	  after	  Aβ	   treatment,	  neurons	  are	   exposed	   to	   an	   extra	   Ca2+	   load	   which	   may	   increase	   their	   susceptibility	   to	  glutamatergic	   activation.	   This	   is	   especially	   important	   in	   an	   AD	   model,	   in	   which	  altered	   glutamate	   transporter	   expression	   has	   been	   linked	   to	   excess	   levels	   of	   the	  excitatory	  neurotransmitter	  and	  neuronal	   injury	   (Jacob	  et	  al.,	   2007;	  Masliah	  et	  al.,	  1996;	  Scott	  et	  al.,	  2011).	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   CpAMPARs	  may	  also	  mediate	  neurodegeneration	  via	  their	  conductance	  of	  the	  divalent	   cation	   Zn2+,	   which	   is	   co-­‐released	   with	   glutamate	   at	   certain	   excitatory	  synapses	  and	  accumulates	   in	  hippocampal	  neurons	   (Jia	   et	   al.,	   2002;	  Kim	  and	  Koh,	  2002;	  Lee	  et	  al.,	  2003;	  Pan	  and	  Patterson,	  2013;	  Sensi	  et	  al.,	  1999).	  Zn2+-­‐binding	  to	  Aβ	  accelerates	  its	  aggregation	  by	  unfolding	  the	  helical	  structure	  of	  the	  peptide	  and	  stabilizing	   the	   formation	   of	   vital	   salt	   bridges	   within	   and	   between	   Aβ	   peptides,	  therefore	   facilitating	   its	   aggregation	   (Pan	  and	  Patterson,	   2013).	   Zn2+	  accumulation	  within	  neurons	  can	  occur	  via	   translocation	  through	  the	  postsynaptic	  membrane	  or	  through	   release	   from	   intracellular	   pools	   (Lee	   et	   al.,	   2003).	   CpAMPARs	   are	   highly	  Zn2+	  permeable	  and	  may	  therefore	  be	  the	  primary	  entry	  site	  of	  synaptic	  Zn2+	  (Jia	  et	  al.,	  2002;	  Sensi	  et	  al.,	  1999;	  Yin	  et	  al.,	  2002).	  Similar	  to	  Ca2+,	  Zn2+appears	  to	  produce	  neuronal	   injury	   through	   numerous	  mechanisms	   including	   enzyme	   induction,	   ROS	  generation	  and	  PARP	  activation	  (Kim	  and	  Koh,	  2002).	  Typically	   the	   main	   source	   of	   Ca2+	   within	   the	   neuron	   is	   mediated	   through	  voltage	   gated	   Ca2+	   channels	   and	   NMDARs,	   the	   latter	   of	   which	   is	   activated	   by	  glutamate	   and	   necessary	   for	   changes	   in	   plasticity	   during	   learning	   and	   memory.	  There	   are	   several	   reasons	   why	   CpAMPARs	   may	   play	   a	   greater	   role	   in	  neurodegeneration	   than	  NMDARs	  after	   glutamatergic	   activation.	   First,	   an	   increase	  in	  their	  expression,	  as	  shown	  here	  in	  the	  Aβ-­‐mediated	  enhancement	  of	  HSP,	  would	  subject	   neurons	   to	   a	   new	   Ca2+	   source	   and	   possibly	   tip	   the	   balance	   toward	  degeneration.	   Additionally,	   because	   NMDARs	   are	   blocked	   by	  Mg2+	   ions	   at	   resting	  membrane	   potentials,	   they	   conduct	   very	   little	   Ca2+	   without	   strong	   postsynaptic	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depolarization.	   Lastly,	   the	   high	   Zn2+	   permeability	   of	   CpAMPARs	   doesn’t	   apply	   to	  NMDARs,	  which	  are	  actually	  blocked	  by	  Zn2+	  (Amico-­‐Ruvio	  et	  al.,	  2011).	  
	  
	  
Aβ-­‐mediated	   enhancement	   of	   HSP	   produces	   an	   increased	   susceptibility	   to	  
neuronal	  injury	  AD	  is	  characterized	  by	  three	  major	  hallmarks:	  Aβ	  plaques,	  tau	  fibrillary	  tangles	  and	  neurodegeneration.	  Areas	  of	  the	  brain	  showing	  elevated	  levels	  of	  degeneration	  are	  typically	   located	   near	   regions	   of	   high-­‐density	   Aβ	   plaques	   and	   tau	   tangles	   and	  typically	  have	  a	   large	  amount	  of	  glutamatergic	   input.	  Therefore	   initial	   studies	   into	  the	   neuronal	   injury	   in	   AD	   focused	   on	   the	   glutamatergic	   system	   and	   pathways	  involved	   in	   its	   regulation.	   Findings	   have	   shown	   that	   excitatory	   amino	   acid	  transporters	  1	  and	  2	  (EAAT1	  and	  EAAT2),	  proteins	  responsible	  for	  the	  reuptake	  of	  excess	   glutamate	   from	   the	   synaptic	   cleft	   after	   presynaptic	   release	   of	   the	  neurotransmitter,	   are	   reduced	   in	   AD	   brains.	   This	   has	   led	   to	   the	   hypothesis	   that	  excess	   glutamate	   left	   in	   the	   synapse	   causes	   over-­‐activation	   of	   postsynaptic	  receptors	   and	   eventually	   leads	   to	   neuronal	   injury	   and	   death	   (Jacob	   et	   al.,	   2007;	  Masliah	   et	   al.,	   1996;	   Scott	   et	   al.,	   2011).	   This	   was	   tested	   with	   the	   application	   of	  glutamate	   to	   neuronal	   cultures	   after	   Aβ-­‐mediated	   enhancement	   of	   HSP.	   Excess	  glutamate	   in	   the	  brain	  can	  be	  detrimental	   to	  neuronal	  health	  and	  proper	   function.	  However,	   if	   HSP	   overcompensates	   for	   fluctuations	   in	   activity	   and	   drives	   a	   higher	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than	  normal	  number	  of	  AMPARs	  to	  the	  postsynaptic	  membrane,	  then	  the	  effects	  of	  excess	   glutamate	   will	   be	   potentiated.	   With	   an	   additional	   source	   of	   calcium	   flux	  coming	  from	  elevated	  CpAMPAR	  expression,	  the	  system	  would	  be	  highly	  vulnerable	  to	   excitotoxic	   injury.	   Additionally,	   a	   higher	   surface	   expression	   of	   AMPARs	   would	  produce	   greater	   postsynaptic	   depolarization	   and	   subsequent	   NMDAR	   activation	  through	   the	   removal	   of	   Mg2+	   blockade,	   thus	   allowing	   elevated	   levels	   of	   NMDAR-­‐mediated	  Ca2+	  flux	  into	  the	  neuron.	  	  During	  normal	  basal	  conditions,	  neurons	  have	  very	  low	  expression	  levels	  of	  CpAMPARs,	   but	   expression	   of	   these	   receptors	   is	   dynamic	   in	   response	   to	  physiological	   changes	   in	  activity	  or	  pathological	  disruptions	   (King	  et	  al.,	  2006;	  Liu	  and	   Cull-­‐Candy,	   2000;	   Man,	   2011;	   Plant	   et	   al.,	   2006;	   Spaethling	   et	   al.,	   2008).	  CpAMPARs	  have	  been	  shown	  to	  be	  regulated	  at	  the	  level	  of	  GluA2	  mRNA	  expression	  in	   ischemia	   (Gorter	   et	   al.,	   1997;	   Pellegrini-­‐Giampietro	   et	   al.,	   1997),	   or	   through	  defects	  in	  mRNA	  editing	  in	  ALS	  (Kawahara	  et	  al.,	  2004;	  Kwak	  and	  Kawahara,	  2005;	  Takuma	   et	   al.,	   1999).	   During	   the	   early	   stages	   of	   AD,	   the	   surface	   levels	   of	   Ca2+-­‐permeable	   AMPARs	  may	   be	   altered	   during	   HSP.	   An	   acute	   increase	   in	   CpAMPARs	  initiates	   a	   normal	   HSP	   response	   followed	   by	   internalization	   of	   GluA2-­‐lacking	  CpAMPARs	   and	   further	   insertion	   of	   GluA2-­‐containing	   receptors.	   An	   AD	   diseased	  brain	   may	   fail	   to	   internalize	   these	   receptors	   after	   initiation	   of	   the	   homeostatic	  response	   (Figure	   10).	   This	   could	   account	   for	   increased	   synaptic	   currents	   but	   also	  the	  excess	  Ca2+	  influx	  from	  these	  receptors	  may	  push	  the	  tipping	  point	  of	  the	  scale,	  making	  neurons	  more	  vulnerable	   to	  cell	  death,	  shown	  during	  glutamate	  challenge.	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Additionally,	  the	  GluA2	  subunit	  itself	  may	  play	  a	  role	  in	  downstream	  effects	  rather	  than	   solely	  via	   elevated	   intracellular	  Ca2+	   levels.	   Further	   studies	  utilizing	  mutated	  GluA2	   constructs	   or	   Ca2+	   chelators	   after	   increased	   CpAMPAR	   expression,	   could	  better	   elucidate	   these	  pathways.	  Cell	   death	  assays	  performed	  with	  glutamate	  plus	  additional	  blockers	  such	  as	  the	  selective	  NMDAR	  antagonist	  APV,	  or	  activation	  with	  AMPA	   itself,	  would	   be	   useful	   in	   further	   investigations	   of	   the	   channels	   involved	   in	  neuronal	  injury	  after	  dysregulated	  HSP.	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Figure	  10.	  Model	  of	  Aβ-­‐mediated	  HSP	  during	  activity	  deprivation	  with	  TTX.	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CHAPTER	  FIVE:	  CONCLUSIONS	  AND	  FUTURE	  WORK	  	  	  This	   research	   shows	   that	   exogenous	   Aβ	   applied	   to	   primary	   neurons	   during	   TTX-­‐mediated	   activity	   deprivation	   can	   enhance	   the	   HSP	   response.	   Furthermore,	   this	  elevated	   level	   of	   scaling	   shows	   an	   increase	   in	   the	   amount	   of	   CpAMPAR	   surface	  expression	   which	   correlates	   with	   an	   increased	   vulnerability	   after	   glutamate	  challenge.	  These	  findings	  show	  a	  novel	  idea	  of	  how	  Aβ	  regulates	  synaptic	  function	  in	  the	   AD	   brain.	   Previous	   reports	   have	   associated	   Aβ	   with	   AMPAR	   receptor	  internalization,	  spine	  loss	  and	  eventual	  neurodegeneration.	  However,	  these	  results	  indicate	   that	   initial	   aberrations	   in	   homeostatic	   responses,	   namely	   over-­‐compensation	   to	   changes	   in	   global	   inactivity,	   may	   be	   the	   underlying	   cause	   of	  synaptic	  phenotypes.	  	   A	  number	  of	   follow	  up	  studies	  should	  be	  conducted	  to	  further	  illustrate	  the	  role	   Aβ	   plays	   in	  HSP.	  Most	   importantly,	   these	   experiments	   should	   be	   repeated	   in	  neurons	   from	   transgenic	   mice	   containing	   the	   Swedish	   hAPP	   and	   PS1	   mutations.	  These	  neurons	  have	  more	  physiologically	  similar	  conditions	  to	  Aβ	  production	  in	  AD	  brains,	   and	   the	   ability	   to	   repeat	   these	   results	   in	   an	   AD	  mouse	  model	  would	   lend	  greater	   support	   to	   these	   findings.	   Investigating	   HSP	   in	   transgenic	   neurons	  would	  alter	   the	   paradigm	   tested	   presently,	   such	   that	   TTX-­‐mediated	   activity	   deprivation	  would	   be	   induced	   after	   neurons	   have	   been	   exposed	   to	   elevated	   Aβ	   levels	   for	   an	  extended	  amount	  of	  time,	  compared	  to	  the	  application	  of	  Aβ	  with	  the	  onset	  of	  HSP	  shown	  here.	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   Another	   interesting	   question	   to	   investigate	   is	   whether	   Aβ	   shifts	   the	  homeostatic	  set	  point	  in	  which	  neurons	  intrinsically	  scale	  to	  after	  changes	  in	  global	  activity,	  and	  if	  this	  change	  is	  transient	  or	  permanent.	  In	  other	  words,	  the	  enhanced	  response	  may	  not	  be	  due	  to	  overshooting	  a	  target	  level	  of	  increased	  synaptic	  weight,	  rather	   the	   set	   point	   may	   actually	   be	   increased	   in	   the	   presence	   of	   Aβ	   due	   to	  alterations	   in	   the	   cellular	   machinery	   involved	   with	   monitoring	   and	   regulating	  neuronal	  activity.	  A	  proposed	  experiment	  would	  be	  to	  produce	  homeostatic	  scaling	  in	   the	   presence	   of	   TTX/Aβ	   in	   the	   paradigm	   shown	   here,	   but	   prior	   to	   recording,	  replace	   fresh	   media	   in	   the	   culture	   for	   1-­‐2	   days	   before	   mEPSCs	   are	   recorded.	  Theoretically,	   activity	   levels	   should	   return	   to	   basal	   levels	   with	   the	   removal	   of	   all	  drugs	  and	  Aβ,	  and	  subsequently,	  synaptic	  scaling	  would	  return	  to	  basal	  levels.	  It	   is	  possible	   that	   Aβ	   could	   disrupt	   the	   neuronal	   set	   points	   thereby	   producing	   a	  permanent	  change	  in	  the	  scaling	  response.	  	   This	  data	  shows	  that	  PI3K	  activation	  is	  not	  up-­‐regulated	  in	  the	  Aβ-­‐mediated	  enhancement	  of	  HSP	  but	  is	  necessary	  for	  a	  scaling	  response.	  Further	  studies	  into	  the	  changes	   in	   receptor	   internalization	   and	   insertion	   need	   to	   be	   conducted.	   As	  mentioned	   previously,	   recordings	   and	   immunocytochemistry	   after	   HSP	   in	   the	  presence	  of	  a	  protein	  synthesis	  inhibitor	  could	  elucidate	  the	  requirement	  for	  protein	  synthesis	  to	  enhance	  the	  scaling	  response.	  Alternatively,	   labeling	  surface	  receptors	  and	   following	   their	   internalization	   after	   scaling	   could	   provide	   insight	   on	  whether	  there	   is	   a	   subunit-­‐specific	   transition	   during	   HSP,	   such	   as	   a	   higher	   rate	   of	   GluA2	  internalization	  to	  produce	  more	  CpAMPAR	  signaling.	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   Calcium	   is	   a	   key	   signal	   in	   synaptic	   plasticity	   as	   well	   as	   neuronal	   injury,	  therefore	   its	   role	   in	   Aβ-­‐mediated	   HSP	   requires	   further	   investigation.	   Upon	  glutamatergic	   activation,	   it	   is	   presumed	   that	   neuronal	   injury	   is	   due	   to	   increased	  intracellular	   Ca2+	   levels.	   This	   research	   has	   shown	   that	  HSP	   after	   co-­‐application	   of	  TTX	   and	  Aβ	   increased	   synaptic	   scaling	   but	   also	   neuronal	   vulnerability.	   Therefore,	  changes	   in	   Ca2+	   flux	   require	   further	   evaluation.	   A	   cell	   death	   assay	   could	   be	  performed	  with	  AMPA	  or	   glutamate	  with	   the	   co-­‐application	   of	   APV,	   to	   isolate	   the	  activation	  of	  AMPARs.	  In	  the	  assays	  performed	  in	  this	  research,	  glutamate	  activated	  both	   NMDARs	   and	   AMPARs,	   therefore	   a	   large	   amount	   of	   Ca2+was	   coming	   from	  NMDARs.	   Increases	   in	  cellular	  Ca2+could	  also	  be	  observed	  with	  a	  calcium	  dye	  such	  as	  Fluo-­‐4	  AM	  or	  Fura-­‐2	  AM.	  Although	  the	  increased	  CpAMPAR	  abundance	  may	  not	  be	  sufficient	  to	  produce	  significantly	  larger	  amounts	  of	  cell	  death,	  higher	  total	  levels	  of	   AMPARs	   may	   lead	   to	   more	   NMDAR	   activation,	   and	   over	   long	   periods	   of	   time	  produce	  neurodegeneration	  typically	  seen	  in	  AD.	  	   Current	  research	  into	  AD	  has	  produced	  many	  new	  and	  exciting	  findings	  into	  the	   mechanisms	   of	   this	   devastating	   disease.	  With	   a	   greater	   understanding	   of	   the	  underlying	  pathways	  that	  drive	  AD	  progression	  and	  cognitive	  failure,	  there	  may	  be	  a	  shift	   in	  the	  focus	  of	  therapeutic	  drug	  targets.	  Current	  pharmaceutical	  development	  strategies	   are	   aimed	   at	   developing	   drugs	   that	   inhibit	   the	   production,	   aggregation,	  clearance	  or	  neurotoxicity	  of	  Aβ	  (Golde,	  2006).	   In	  the	  future,	   it	  may	  be	  possible	  to	  slow	  disease	  progression	  and	  neurodegeneration	  by	  targeting	  mechanisms	  involved	  in	  HSP.	  This	  approach	  produces	  its	  own	  limitations,	  because	  HSP	  is	  instrumental	  in	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the	  maintenance	   and	   stability	   of	   neuronal	   network	   function.	   Nevertheless,	   if	   HSP	  proves	  to	  be	  an	  inadequate	  therapeutic	  target,	  maintaining	  a	  proper	  compensatory	  response	  during	  HSP	  may	  become	  a	  necessity	  for	  any	  drug	  canidate.	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